# The Royal College of Ophthalmologists

**This guideline is currently under review with an expected publication date of summer 2012.**


# Age-Related Macular Degeneration Guidelines for Management

## February 2009

Scientific Department
The Royal College of Ophthalmologists
17 Cornwall Terrace
Regent's Park
London NW1 4QW

Telephone: 020 7935 0702
Facsimile: 020 7487 4674
www.rcophth.ac.uk

**AMD Guidelines Group**

**Age-Related Macular Degeneration: Guidelines for the Management**

6.4 Genetic
    6.4.1 Major genetic risk factors for AMD
    6.4.2 Gene-environment interactions
    6.4.3 Pharmacogenetic relationships
6.5 Others
    6.5.1 Cataract surgery
    6.5.2 Sunlight
    6.5.3 Gender/sex hormones
    6.5.4 Race
    6.5.5 Social class

**7 Natural history of vision loss**
7.1 Visual acuity outcomes without treatment
7.2 Lesion morphology and vision loss
7.3 Contrast sensitivity
7.4 Near vision and reading speed
7.5 Self reported visual functioning and quality of life

**8 Therapies for acute neovascular AMD**
8.1 Laser photocoagulation
    8.1.1 Extrafoveal
    8.1.2 Juxtafoveal
    8.1.3 Subfoveal
8.2 Photodynamic therapy (PDT)
    8.2.1 Combination PDT and triamcinolone
8.3 Surgery
8.4 Ionising radiation
8.5 Anti-angiogenic therapies
    8.5.1 Pegaptanib sodium
    8.5.2 Anecortave acetate
    8.5.3 Ranibizumab
    8.5.4 Bevacizumab
8.6 Combination treatments
    8.6.1 PDT and ranibizumab
    8.6.2 Triple therapy
8.7 Emerging Therapies

**9 Treatment delivery**
    9.1 Initiating treatment
    9.2 Choice of therapy
    9.3 Intravitreal drug delivery
    9.4 Outcomes to be measured
    9.5 Follow up intervals
    9.6 Re-treatment decision making
    9.7 Drug holding and cessation of therapy

## 1.0
## Membership of the Guidelines Group

### *Chair*

Professor Usha Chakravarthy- Consultant Ophthalmologist Royal Victoria Hospital Belfast, Professor of Ophthalmology and Visual Sciences Queen's University Belfast.

### *Deputy Chair*

Clara McAvoy- Consultant Ophthalmologist Royal Victoria Hospital Belfast

### *Retinal specialists*

Winfried Amoaku- Associate Professor/ Reader in Ophthalmology and Visual Sciences University of Nottingham, Consultant Ophthalmologist University Hospital, Queen's Medical Centre, Nottingham.
Clare Bailey- Consultant Ophthalmologist, Bristol Royal Infirmary.
Professor Paul Bishop- Manchester Royal Eye Hospital, CMMC Trust & Research School of Clinical and Laboratory Sciences, University of Manchester
Chris Brand- Consultant Ophthalmologist, Royal Hallamshire Hospital.
Professor Victor Chong- Consultant Ophthalmologist, Oxford Eye Hospital, Radcliffe Infirmary.
Susan Downes- Consultant Ophthalmologist, Oxford Eye Hospital, Radcliffe Infirmary.
Professor Andrew Lotery- Consultant Ophthalmologist, Southampton General Hospital and Southampton University.
James Talks- Consultant Ophthalmologist, Newcastle Royal Infirmary.

### *College Scientific Advisor*

John Sparrow- Consultant Ophthalmologist, Bristol Royal Infirmary.

### *Vision Scientists*

Gary Rubin- Helen Keller Professor of Ophthalmology UCL Institute of Ophthalmology, London.
Jonathan Jackson- Principal Optometrist, Royal Victoria Hospital Belfast, Honorary Professor Faculty of Health and Biomedical Sciences, Queen's University Belfast.
Jennifer Evans - Epidemiologist and Cochrane Eyes and Vision Group Editor, Lecturer, International Centre for Eye Health, London School of Hygiene and Tropical Medicine.

***Patient Representative***

Tom Bremridge- Chief Executive, Macular Disease Society.

***External reviewer***

Professor Phillip Rosenfeld

## 2.02.0 Rationale for the guidance

Age-related macular degeneration (AMD) is the commonest cause of severe visual impairment in older adults in the developed world. The two main late AMD phenotypes geographic atrophy and exudative AMD are responsible for two-thirds of registrations of visual impairment or blindness in the UK. It is estimated a quarter of a million older adults in the UK alone suffer from blindness due to this condition [1].
The past decade has witnessed an increase in therapeutic options with novel strategies to target neovascularisation without damaging the neural retina or other equally important tissues. The management of AMD is a fast changing field and there are strong epidemiological and clinical reasons to issue new guidelines to keep pace with these developments. Estimates from The Royal National Institute of the Blind and National Institute of Health and Clinical Excellence indicate there may be 26,000 people with exudative AMD now eligible for treatment in the UK each year- therefore given a total population of 60 million this would equate to 450 new cases per million per year.
http://www.rcophth.ac.uk/docs/publications/published-guidelines/CommissionContempAMDServicesV3Final.pdf

The guidelines are intended to set the standards for best practice in the NHS and in the private sector. They will be of use in education of ophthalmic trainees and those in other disciplines. The guidelines are also intended to give patients, carers and consumer organisations a resource for improved current information. The guidelines will act as a benchmark for service planning by providers, guide purchasers in the commissioning of services and set national standards for audit.

## 3.0 Sources of information

Contributors identified relevant literature from a range of sources: Pubmed, the Cochrane Library, Current Contents and their own personal collections. Additional information for the epidemiology/ risk factor sections was provided from searches conducted by the Eyes and Vision Specialist Library (http: //evslarchive.moorfields.nhs.uk/amd docs 0607/ref3.pdf)

## 4 Epidemiology

### 4.1 Definitions

Age-related macular degeneration (AMD) is the term applied to ageing changes without any obvious cause that occur in the central area of the retina (macula) in people aged 50 years and above. In the early stages lipid material accumulates as deposits beneath the retinal pigment epithelium **(RPE) and** within Bruch's membrane. When focal collections of lipid material are present these are referred to as drusen and can be seen as pale yellow spots on a clinical examination of the retina. The retinal pigment epithelium also undergoes morphological alteration and clinically this is evident as areas of hyperpigmentation and hypopigmentation. Generally drusen and RPE irregularities are not associated with disturbances of central visual function. A proportion of people with these early changes will progress to severe central vision loss. When vision loss occurs it is usually due to the development of geographic atrophy and/or exudative disease.

Geographic atrophy (GA) is a sharply demarcated area of partial or complete depigmentation reflecting atrophy of the retinal pigment epithelium. The margins of the depigmented area are usually scalloped and the large choroidal vessels are visible through the atrophic RPE

Exudative disease is also termed neovascular AMD. In the vast majority of eyes with neovascular disease, new blood vessels that have their origin from the choroid (choroidal neovascularisation (CNV)) are seen. CNV breaches the normal anatomical barrier of Bruch's membrane and invades the subpigment epithelial and or subretinal spaces. Neovascularisation can also arise de novo in the macular retina and is referred to as retinal angiomatous proliferation (RAP). RAP can establish contact with choroidal vessels to form chorioretinal anastomoses (CRA). Regardless of origin whether retinal or choroidal, the new vessels are unlike normal retinal vessels in that they are fenestrated and allow blood constituents to leak out. This egress of blood and serum causes the separation of Bruchs, RPE, and retina from each other and also results in the accumulation of intraretinal fluid the consequence of which is a generalised thickening of the retina or the formation of cystic spaces. These pathological manifestations cause the photoreceptors to become misaligned and eventually degenerative changes occur with cell loss and eventual fibrosis. The final result is a scar often with a circular disposition and hence the term disciform macular degeneration.

### 4.2 Classification

There are a number of classification schemes for AMD. The aim of these schemes is to provide a common nomenclature so that the prevalence of AMD and its development over time can be compared between different studies often undertaken in widely differing geographical locations. The main classification

schemes share many similar features and are largely based on the Wisconsin Age-Related Maculopathy Grading Scheme (WARMGS).[2] This grading system is based on the presence and severity of the characteristic features of AMD namely drusen, pigmentary irregularities, GA and neovascularisation. The WARMGS has been in use for over 2 decades and owing to its complexity and multiple scales attempts have been made to simplify it for use in both research and clinical situations. The first attempt to undertake this was in the mid nineties when a consensus group met and developed the early age-related maculopathy (ARM**)** international classification system.[3] This system attempted to distinguish the early features of macular ageing namely drusen and pigmentary irregularities from the late features of GA and CNV by using the term age-related maculopathy to signify only early disease.

### 4.2.1 *Early Age Related Macular Degeneration*

Features of early age related macuar degeneration include:

- Soft drusen ≥ 63 µm (drusen are discrete lesions consisting of lipids and protein deposited under the retina[4])
- Areas of increased pigment or hyperpigmentation (in the outer retina or choroid) associated with drusen
- Areas of depigmentation or hypopigmentation of the retinal pigment epithelium (RPE)

### 4.2.2 *Late Age Related Macular Degeneration: Geographic atrophy (GA) or Neovascular AMD, wet AMD, disciform AMD or exudative AMD)*

Late Age related macular degeneration is another term used for the late stages namely GA or neovascular AMD. A description of the clinical features of GA is given in section 4.1.1.

Clinical features that indicate the presence of neovascular AMD include any or all of the following when these are seen within the macular area of the fundus. Intraretinal, subretinal or sub –RPE haemorrhages and/or fluid with or without peri retinal fibrosis in the absence of other retinal (vascular) disorders.

Both WARMGS and the ARM classification system yield considerable details on size and surface features of drusen and the presence and absence of pigmentary irregularities. The longitudinal epidemiological studies which used these classification systems developed severity scales based on the multiple permutations and combinations of these features in order to predict progression to late AMD. Although the severity scales are moderately good at predicting the progression from early to late AMD, these groupings cannot be achieved without standardised systematic grading of stereoscopic fundus images, thus restricting their applicability in the clinical setting. The development initially of a 4 stage

clinically achievable classification followed by the development of a simple risk prediction algorithm has been greeted with enthusiasm. The Age Related Eye Disease Study (AREDS) is an ongoing randomised controlled clinical trial of some 4000 participants ranging from persons with no evidence of early or late AMD in either eye to those with late AMD in one eye.[5]

The 4 stage classification of AMD from AREDS is shown below.

**No AMD (AREDS category 1)** none or a few small drusen (<63 microns in diameter)

**Early AMD (AREDS category 2)** any or all of the following: multiple small drusen, few intermediate drusen (63 to 124 microns in diameter), or RPE abnormalities.

**Intermediate AMD (AREDS category 3)** any or all of he following: extensive intermediate drusen, and at least one large druse (≥ 125 microns in diameter), or geographic atrophy not involving the centre of the fovea.

**Advanced AMD (AREDS category 4);** GA involving the fovea and/or or any of the features of neovascular AMD.

Drusen are commonly found in older people and are not always associated with progression to late AMD and visual loss. As mentioned previously the risk of progression from early AMD to late AMD has been analysed in participants of the AREDS study and a predictive algorithm suitable for clinical use has been developed (figure 1).[6] Three factors predict the progression of AMD: presence of large drusen (>125 microns which approximates the size of a normal retinal vein at the disc margin), retinal pigment epithelial abnormalities and the presence of late AMD in one eye. A five step score (0 to 4) has been proposed which can be used to identify the approximate 5-year risk of developing advanced AMD:

| **Score** | **Risk** |
|---|---|
| 0 | 0.5% |
| 1 | 3% |
| 2 | 12% |
| 3 | 25% |
| 4 | 50%. |

For people who have features of early AMD in one or both eyes namely large drusen or pigment abnormalities a score of 1 is assigned per feature per eye. In those people with advanced AMD in one eye, the 5-year risk for the development of advanced AMD in the fellow eye is estimated by assigning a score of 2 for existing GA or CNV in the first eye and to this is added to the scores for large drusen or pigment abnormalities in the second eye. Figure 1 shows how the overall score is computed.

**Figure 1**




Arch Ophthalmol 2005 123; 1573-1574



**Practical Points**

**The AREDS classification of macular degeneration into early, intermediate and advanced forms is of value when discussing vitamin supplementation.**

**AREDS revealed a beneficial effect of very high doses of antioxidants (daily dose vitamin C 500mg, vitamin 400 IU, Beta-carotene 15mg (25,000 IU)) and zinc 80mg (along with 2mg copper to prevent anaemia) in reducing patient's relative risk of progression to advanced AMD by 25%. These supplements may be indicated in patients with advanced AMD in the fellow eye.**

## 5 Diagnosis

### 5.1 Clinical

**Geographic atrophy.** The presentation of GA is usually insidious and often detected during routine fundus examination. When GA is bilateral and involves the fovea of both eyes, patients may complain of deterioration of central vision. A common mode of presentation is difficulty with reading initially with the smallest sizes of print and then later with larger print and or words. The confirmation of the diagnosis of GA is by clinical examination using a high definition fundus lens for stereo biomicroscopy. This will reveal the characteristic area or areas of pallor with sharply defined and scalloped edges. When the area of GA is larger than 500 microns, large choroidal vessels are clearly visible within the area of pallor. Usually areas of drusen and focal hyperpigmentation are visible in the retina adjacent to the patch of GA. The use of scanning laser ophthalmoscopy to generate fundus autofluorescence images and the use of en-face imaging using spectral domain OCT have made it easier to diagnose GA as these can reveal areas of GA which may not be clinically visible on biomicroscopy.

**Exudative AMD.** The onset of exudative AMD is heralded by the appearance of central visual blurring and distortion. Most patients will complain that straight lines appear crooked or wavy. Sometimes patients do not notice visual symptoms when the first eye is affected. When exudative AMD occurs in the second eye, patients suddenly become unable to read, drive, and see fine detail such as facial expressions and features. Prodromal symptoms include the phenomena of a patient waking at night and being unable to read the clock due to a central dark patch in the visual field which clears within a few minutes as they adapt. This symptom can be present in patients with AMD who do not necessarily develop exudative AMD.

Examination of the macula usually reveals an exudative macular lesion along with other features of early AMD such as drusen and pigmentary irregularities. Sometimes these latter features are not observed once exudative AMD has supervened. However the fellow eye if free of advanced disease will usually exhibit some or all of these early clinical signs and their presence is helpful in confirming that the neovascular lesion is due to AMD. Following slit lamp biomicroscopy the presence or absence of the following signs should be noted:

- Subretinal or sub-RPE neovascularisation which may be visible as grey green lesions. Occasionally the lesion will have a dark pigmented edge which is thought to be due to proliferation of the RPE at the edge of the membrane.
- Serous detachment of the neurosensory retina.
- RPE detachment.
- Haemorrhages- subretinal pigment epithelial, subretinal, intraretinal or pre-retinal. Breakthrough bleeding into the vitreous may also occur.

- Hard exudates (lipids) within the macular area related to any of the above, and not related to other retinal vascular disease.
- Epiretinal, intraretinal, subretinal or sub-pigment epithelial scar/glial tissue or fibrin-like deposits.
- Retinal angiomatous proliferations and retinochoroidal anatomists.

**Idiopathic Polypoidal Choroidopathy (IPC**). This is an atypical form of neovascular AMD in which highly exudative lesions with haemorrhagic pigment epithelial detachments are seen most typically adjacent to the optic disc, but can occur anywhere within the macula and even outside the macula. High speed fluorescein or indocyanine green angiography typically reveals hyperfluorescent dilated complexes of choroidal vessels that leak in the later phases of the angiograms. These dilated complexes look like polyps or grapes and hence the name. It was originally described in middle aged black populations with a predilection for women. IPC it is considered part of the spectrum of AMD and a strong association with hypertension and ischaemic heart disease has been noted. The use of confocal high speed imaging devices allows IPC to be diagnosed more frequently and it accounts for more than a third of serosanguinous maculopathy in older adults in Asian populations and for some 8-13% of that seen in Caucasians. [7]

### 5.2 Conditions mimicking AMD

A number of disorders can result in macular lesions which have to be distinguished from AMD.

**Exudative Macular lesions mimicking AMD.**

**Diabetic maculopathy**. This is the most common exudative central macular disorder in older adults. Patients with diabetes frequently exhibit retinal microaneurysms, haemorrhages and exudates often set in a background of macular oedema. The presence of more extensive vascular signs outside the macular arcade along with venous engorgement or beading should alert the clinician to a diagnosis of diabetic maculopathy. The visual function is less markedly reduced in eyes with diabetic maculopathy when compared to eyes with CNV involving the fovea. Fluorescein angiography is needed to confirm the absence of choroidal neovascularisation and sub RPE pathology. Sometimes exudative AMD and diabetic maculopathy can coexist as both are common conditions.

**High myopia** can be associated with choroidal neovascularisation. These neovascular complexes are believed to occur as a consequence of the development of minute cracks in thinned Bruchs membrane allowing choroidal vessels to access the subretinal space.

**Inflammatory CNV**. A number of the choroidal inflammatory white dot syndromes (eg. Presumed ocular histoplasmosis, punctate inner choroidopathy,

multifocal inner choroidopathy) can be associated with inflammatory neovascular membranes.

**Central Serous Retinopathy** (CSR) A collection of serous fluid in the sub-neurosensory retina without any evidence of neovascularisation. Chronic central serous retinopathy can sometimes be confused with AMD, again the history, symptoms and a combination of retinal imaging usually helps distinguish between the two.

**Macular telangiectasia**. Idiopathic macular telangiectasia **(MACTEL)** also sometimes termed perifoveal or juxtafoveal telangiectasia can be easily confused particularly with the RAP form of neovascular AMD. In MACTEL abnormal retinal vessels showing telangiectactic changes are detectable in the macular region. Two types are recognised. Type 1 MACTEL occurs in middle age persons and the condition is usually unilateral and exhibits exudative features as the vessels are leaky and intraretinal fluid accumulation occurs with a cystic maculopathy evident using OCT imaging. Type 2 MACTEL occurs in older people and is usually bilateral with evidence of crystalline deposits, pigmentary charges, and right angled venules evident temporal to the fovea and extending to the entire perifoveal region. While leakage is detectable on fluorescein angiography, there is no evidence of increased retinal thickening. Cystic spaces are evident within the retina using OCT and these spaces are thought to reflect the loss of retinal tissue. Occasionally, sub-retinal neovascularization develops and arises from the retinal circulation.[8]

**Non exudative macular lesions mimicking AMD**

Pattern dystrophy (PD) affects the macula and can be mistaken for exudative AMD. The most common types of PD seen are adult vitelliform macular dystrophy (AVMD) and less commonly butterfly shaped pattern dystrophy. PD is a, condition which has a genetic basis, despite this a family history is often not present. PD is usually associated with a better visual outcome than AMD, unless complicated by choroidal neovascularisation or atrophic changes. Differentiating AVMD in particular from AMD can be difficult. Symptoms may be similar particularly if CNV or atrophy complicates PD, but often AVMD is identified in an asymptomatic individual at a routine fundoscopic review. Optical coherence tomography and autofluorescence imaging, if available can be very helpful in distinguishing PD from AMD. Fluorescein angiography can show a typical ‘corona sign’ in AVMD, and the branching lines seen in butterfly shaped PD are associated with a hyperfluorescence distributed in the area of the deposits, which does not show leakage throughout the phases of the angiogram. Occasionally, fluorescein angiographic staining of the vitelliform lesion can be mistaken for active leakage from CNV.

## 5.3 Retinal imaging

Retinal imaging is an integral part of patient management and is required for diagnosis and monitoring response to therapy. Commonly used retinal imaging techniques are colour fundus photography, fluorescein angiography (FA), indocyanine green angiography (ICGA), optical coherence tomography (OCT), and fundus autofluorescence (FAF). Previously fundus photography and FA were undertaken using traditional fundus cameras and the images were captured on 35 mm film. However the advent of high resolution digital cameras and the marked improvements in electronic capture and storage systems with the corresponding advances in image capture software with increased capacity for storage has resulted in the almost complete transition to digital acquisition systems. Important advantages of digital angiography are the ability to instantaneously display captured images for review prior to saving them, use of standardized software to measure areas of interest, easy archiving, storage and retrieval of the images.

### 5.3.1 Fundus photography

Colour fundus photography provides a record of the appearance of the macular retina. Stereoscopic images of the macula viewed appropriately can help localise pathology to the different tissue layers. For the purposes of recording macular pathology stereoscopic pairs of images taken at 35 degrees centered on the macula are recommended.

### 5.3.2 Fundus Fluorescein angiography (FFA)

FFA is currently the gold standard for diagnosing CNV in AMD. A fluorescein angiogram is a sequence of images captured of the fundus over a 10 minute period after injection of the non toxic dye fluorescein isothiocyanate into a suitable peripheral vein.

In the 1980's fluorescein angiography (FA) was typically undertaken using analogue capture on 35 mm film. FFA on film produces a negative picture with the hyperfluorescence visualised as black areas. The film can be printed to give a positive image in which hyperfluorescence is visualised as a bright area but with a loss of image quality. Digital images by contrast are positive therefore hyperfluorescence is seen as a bright area.
Colour photographs must accompany the FFA as they yield important additional information on the composition of the macular lesion allowing interpretation of the FFA. Haemorrhage, pigment and exudate all of which are seen as dark areas on FA are easily distinguished from each other on colour images. Early phases of the angiogram must be captured as they are important for the visualization of the choroidal phase and the early arterial phases when pathology is better seen before obscuration of details by leakage and pooling of fluorescein dye.

Late images (10 minutes) are also important for distinguishing late leakage from drusen (which can take up fluorescein but which fade towards the end of the fluorescein run) and RPE window defects, and inactive scars. This is necessary to distinguish active from inactive pathology, which may be important for initiating or continuing treatment.
Stereo images are necessary to identify the tissue compartment in which pathological features are seen eg. RPE elevation, elevation of the neurosensory retina.

**Preparation for FFA**: It is important to document a patients' medical history and obtain consent. The history should exclude fluorescein allergy on a previous exposure or allergy to iodine if an indocynanine green angiogram is also requested and the indocyanine green preparation is known to contain iodine. A record of the patient's current medications should be made and blood pressure recorded. While existing cardiovascular or renal disease are not reasons for withholding FFA, this information may prove useful in terms of subsequent patient management particularly in the event of an allergic reaction. If a patient is known to have a mild history of allergy from a previous FA, one may still be performed after taking appropriate precautions such as administration of an appropriate drug eg an antihistamine such as chlorpheniramine (piriton). Serious adverse reactions are extremely rare. [9] Yannuzzi et al estimated the risk of death following FA to be 1: 222 000. [10] It is essential therefore that the facilities for resuscitation with a standard protocol should be available. If a patient has a minor allergic reaction observation for at least 30 minutes is recommended before being allowed to leave the unit, as sometimes more severe life threatening reactions may take time to develop. While units perform fluorescein angiography differently the following is a typical protocol that can be used;

- Obtain consent.
- Fill out patient proforma.
- Dilate both pupils for photography.
- A cannula should be sited in a suitable peripheral vein and its location checked to ensure that there is no danger of extravasation.
- The photographer should take the colour stereo pairs of the macular retina and red free images as required and prepare the camera for fluorescein capture by introducing the appropriate filter and barrier lenses.
- A nurse or other qualified personnel should check the patency of the venflon and then inject 5 mls of 10% or 20% Sodium fluorescein through the venflon. Some units find 3ml 20% fluorescein sufficient.
- The photographer starts the timer and captures images as stereo pairs of the macula of the eye in question with a sideways movement of the joystick between pairs (no rotation, change in focus or swivelling of the camera is allowed between capture of the members of one pair). If one eye only is the focus of interest then images are captured of this eye until 60 seconds have elapsed. Rarely the clinician may wish early pairs of both eyes and in this event the photographer may be instructed to obtain stereo

pairs of the fellow eye around 25 to 30 seconds after the run has commenced. Usually stereo pairs are obtained of each macula at 1 min, 2 mins, 5 mins and 10 mins.

- The photographer reviews the run, deletes unwanted or poorly focused images and saves the rest for archiving.

### 5.3.3 Angiographic features of neovascular AMD

Neovascular lesions are classified by their location with reference to the foveal avascular zone – extra-foveal, juxtafoveal or subfoveal. Lesions lying more than 200μm from fixation are defined as extrafoveal, and. may also be described as juxtafoveal or subfoveal when immediately adjacent to or when involving the geometric centre of the fovea. Neovascular lesions located away from the macula are termed peripheral or juxtapapillary.

More refined classification of the neovascular lesion is performed by describing the composition of the exudative lesion after stereoscopic review of the entire sequence of the angiogram. The exudative lesion is defined as the area occupied by the neovascular complex, any associated blood, thick exudate and pigment epithelial detachments that are contiguous to the vessels and obscure its margins. The neovascular complex can consist of retinal angiomatous proliferation (RAP), choroidal neovascularisation (CNV) and idiopathic polypoidal choroidal vasculopathy (IPC)

The initial classification of neovascular AMD lesions was derived by the macular photocoagulation study group prior to the recognition of RAP and IPC as AMD entities. This classification remains helpful and allows CNV to be classified based on the temporal and spatial features of the patterns of fluorescence as observed on the FA.[11] A description of these features is given below.

**Classic CNV** is said to be present when an area of well delineated hyperfluorescence appears in the early phases of the FA usually before 30 seconds have elapsed following injection of the fluorescent dye into a peripheral vein. Classic CNV represents new vessels that have breached the RPE and lie in the subretinal space. Sometimes a typical lacy pattern of hyperfluorescence is observed in the very early phase of the angiogram which corresponds to the vascular profiles before the fluorescein has leaked out of these vessels and obscured the margins. Classic CNV also leak aggressively and hence there is considerable pooling of fluorescein dye in the sub retinal space.

**Occult CNV** as its name suggests is the presence of leakage without clear evidence of neovascular profiles in the early angiographic images. Two types of occult leakage are recognised. The first is a characteristic stippled hyperfluorescence which occurs early and is located at the level of the RPE. The RPE layer is elevated and in the later phases of the angiogram there is increasing hyperfluorescence and pooling of dye in the subretinal pigment epithelial space. The pattern of leakage suggests new vessels between Bruch's

membrane and the RPE and it is therefore considered to be a fibrovascular pigment epithelial detachment (FPED). The second pattern of occult leakage is a more diffuse hyperfluorescence with poorly demarcated boundaries which occurs late in the angiographic phase generally after 2 minutes have elapsed since injection of dye. There is no corresponding hyperfluorescence in the early frames and there is shallow elevation of the RPE. This type of leakage is referred to as late leakage of indeterminate origin (LLIO).

Many lesions are mixed showing combinations of classic and occult features.

It is now common practice to classify lesions by presence or absence of classic and or occult CNV. In the absence of any occult CNV, lesions are termed classic with no occult (100% classic) and conversely occult with no classic (0% classic). When CNV are mixed the lesion is classified by the proportion of classic. When the lesion is composed primarily of classic CNV (i.e. classic greater than 50%) it is termed predominantly classic. When there is 1 to 49% classic the lesions are termed minimally classic.

Gass also classified choroidal neovascular membranes into two types according to their anatomical site. [12] Type 1 membranes are present in the subretinal pigment epithelial space and their excision results in a large retinal pigment epithelial defect. Type 2 membranes are present in front of the retinal pigment epithelium and may be excised without significant damage to the retinal pigment epithelium. Type 2 choroidal neovascular membranes are typically found in children and young adults and therefore associated with conditions such as presumed ocular histoplasmosis, punctate inner choroidopathy, multifocal choroiditis, high myopia, angioid streaks and choroidal rupture.

One type of neovascularisation that has been recognised by the use of high speed video angiography using the scanning laser ophthalmoscope is the RAP lesion. RAP's are seen as intraretinal telangiectatic and tortuous blood vessels within the macula. On viewing stereo pairs of images, the vessels are seen to turn sharply from the inner retina towards the choroidal interface. RAP's are commonly associated with large serous PEDs and extensive areas of small drusen. They leak aggressively and hence the adjacent retina is usually disrupted with cystoid spaces. Serous PEDS can also arise in the absence of vascularisation and ICG angiography is a useful tool for distinguishing vascularised from non-vascularised PEDs.

Some consider idiopathic polypoidal choroidopathy (IPC) as another component of the spectrum of exudative AMD. IPC are seen as focal areas of abnormal dilated choroidal vessels and result in a highly exudative picture with considerable accumulation of lipid and or haemorrhage in the subretinal space. These are best visualised by ICG angiography.

### 5.3.4 ICG angiography

Indocyanine green (ICG) is an alternative dye to fluorescein which is used to visualize the choroidal circulation. This dye binds to plasma protein and hence does not egress through the fenestrae of the choroidal vessels, instead remaining within the vascular compartment. Choroidal vessel morphology is therefore better delineated. ICG is imaged using infra red wavelengths which can pass through the RPE and blood therefore permitting visualization of pathology which can block the transmission of wavelengths that excite fluorescein. ICG also has some limitations and very thick blood or pigment can reduce or block transmission of the infrared wavelengths and the emitted light is of lower intensity compared with fluorescein. The use of the scanning laser ophthalmoscope (SLO) with video capture can however yield images of high resolution. Video ICG also allows better imaging of RAP. As ICG dye does not leak into the subretinal and subpigment epithelial spaces to the same extent as fluorescein the enhanced definition of the vascularised tissue as a hotspot is possible and a combination of FFA and ICG can produce complementary information. A dose of 25mg of ICG in aqueous solution is usually injected intravenously and images acquired for up to 30 minutes.

### 5.3.5 Ocular coherence tomography (OCT)

Optical coherence tomography (OCT) relies on the analysis of wave patterns of reflected laser light to produce an image. A reflectivity profile called an A scan is generated. Early commercial OCT's captured around 100 A scans a minute and had a resolution approaching 30 μm. The next generation of OCT's (OCT 3) captured around 400 A scans and had a resolution of 10 to 15 μm. The new Fourier Domain **(FD)** OCT's which capture around 20,000 A scans a minute have higher resolution permitting the visualization of retinal layers. These do not resolve to the level of the individual cell.
Nonetheless the FD OCT can achieve a resolution of between 5 and 10 μm allowing more detail than ever before to be visualised. The multilayered structure of the retina is clearly visible and the RPE and Bruch's membrane are also partially delineated. Most incident light from the OCT is reflected before it reaches the RPE. While variations in RPE pigmentation may allow some light to reach the choroid this is insufficient to resolve choroidal structure. OCT is excellent at detecting separation of retina from the RPE and the RPE from its basement membrane and identifying interruptions in the RPE layer including a tear. Thickening of the retina and the presence of intra-retinal fluid are also easily detected. CNV are also easily visualized as these are seen as areas of high reflectivity and their relation to the tissue compartments ie. below the RPE, above the RPE, involving the neuroretina can be judged. The composition of the tissue ie. RPE proliferation, endothelial tubes (perfusing CNV), fibrosis or organized haemorrhage cannot be ascertained as all of these tissue components appear to have similar reflectivity characteristics. The OCT poorly delineates the choroidal-RPE interface owing to poor penetration of light to that level.

In some OCT machines the registration of the image is dependant on a black and white fundus photograph taken at the same time, with others a SLO image is obtained with exact correlation with the OCT images and with other machines a pseudo- fundus image is obtained by re-constructing the OCT slices.
Some OCT imaging systems are combined with FFA and or ICG capabilities, which will improve correlation of the different information.

OCT may be used for screening the macula prior to performing more invasive imaging such as FFA. OCT alone may be able to provide sufficient information to permit decisions on clinical management and follow up.

To obtain relevant information appropriate high quality scans with the more recent generation of OCT's are required. Appropriate protocols should be used and technicians should be trained in the acquisition of images. As high speed spectral domain OCT machines perform many thousands of scans across the macula, pathology is less likely to be missed and the technology will contribute in helping distinguish different diagnoses.

### 5.3.6 Autofluorescence

This can give an indication of the health of the RPE. Autofluorescence originates from lipofuscin in RPE cells. Increased autofluorescence represents accumulation of lipofuscin and suggests that the RPE cells are beginning to fail. Absence of autofluorescence results in a black image and is due to loss of RPE cells. The finding of patches of absent autofluorescence may explain central scotoma patterns. While different patterns have been described in early and late AMD the exact utility of autofluorescence is yet to be determined.

### 5.3.7 Structure function relationships

Increasingly imaging devices are being combined to allow better correlation of structure and function. Systems that perform a simultaneous acquisition of FFA and ICG on the SLO combined with OCT are now available commercially. Others have combined macular perimetry with colour imaging and/or OCT and ICG. Multifocal ERG is also possible. Spectral imaging indicating oxygen saturation in the retina and its vasculature is under investigation and adaptive optics is an exciting new development, which allows in vivo imaging of individual photoreceptors.

## Practical Points

**Stereoscopic fluorescein angiography is indicated to determine the extent, type, size and location of CNV.**

**ICG is useful when assessing patients with macular haemorrhage or suspected of having retinal angiomatous proliferative lesions, idiopathic polypoidal choroidopathy, or non-vascularised vs. vascularised PEDs. Good resolution OCT, Stratus 3 or higher specification is mandatory for diagnosis and monitoring response to therapy.**

## 6 Risk factors

Epidemiological studies have revealed a number of risk factors for late AMD. These fall into two categories ocular and systemic.

### 6.1 Ocular

#### 6.1.1 Precursor lesions (also see section 4.1.1 and 4.1.2)

The following precursor lesions (sometimes referred to as early ARM) are risk factors for progression to advanced AMD (both neovascular disease and GA) [13-16]

- large drusen
- soft indistinct drusen
- extensive drusen area
- hyperpigmentation.

A detailed description of the relationships between the above features and development of AMD is given in section 4.2. Until lately the presence of small hard drusen was not considered a risk factor for progression. However one recent study suggests that people with larger numbers of small hard drusen are at increased risk of developing soft indistinct drusen and pigmentary abnormalities.[17] This suggests that there is a continuum from small hard drusen to advanced AMD.

#### 6.1.2 Refractive status

A number of studies have reported an increased risk of AMD associated with hyperopia [18-22] but other studies have not.[23-26] One prospective study has found a modest increase risk of AMD in people with hyperopia. [22]

However the observed association between hyperopia and AMD may well be due to differential misclassification, for example, people with high myopia may be less likely to be classified as having AMD, or the classification of drusen may be different in people with hyperopia.[27]

#### 6.1.3 Iris colour

There is inconsistent evidence for an association between iris colour and development of AMD. Some studies have suggested that there is an association. [28-32] However others have not found such an association.[23, 24, 33-36] The Beaver

Dam Eye Study found an inconsistent relationship between iris colour and 10 year incidence of drusen and pigmentary abnormalities. [37]

### 6.1.4 Macular pigment

Macular pigment is composed of two carotenoids lutein and zeaxanthin which are solely of dietary origin and which are found in a wide variety of green leafy plants such as spinach and kale and in some animal products such as egg yolks.[38] It is thought that they protect the retina from the harmful effects of free radicals released by visible light .[39, 40]

Decreased serum, dietary and retinal levels of these carotenoids have been associated with an increased risk of AMD in some [41-47] but not all observational studies [48-54]. One small trial showed some benefit to supplementation with lutein in people with AMD.[55]

While there is insufficient evidence to recommend lutein and zeaxanthin supplements, eating a diet rich in leafy green vegetables and fresh fruit is likely to improve concentrations of macular pigment in the fundus and is unlikely to do any harm.

The Age-Related Eye Disease Study 2 (AREDS 2) is currently recruiting 4,000 participants in a five-year controlled trial of supplementation with lutein and zeaxanthin (http://www.nei.nih.gov/neitrials/viewStudyWeb.aspx?id=120, accessed 15/2/2007).[56]

## 6.2 Lifestyle

### 6.2.1 Tobacco smoking

Cigarette smoking is a well-established risk factor for the development of AMD.[57-63] Current smokers have a two to three-fold increased risk of developing AMD and there is a dose-response relationship with pack-years of smoking [64-66]. Those with a genetic susceptibility are also more likely to develop AMD if they smoke (see under 6.4.2). Tobacco smoking is the main modifiable risk for AMD. Public health interventions to help people stop smoking will play an important role in preventing the development of AMD.[67]

### 6.2.2 Alcohol intake

Alcohol consumption is a plausible risk factor for AMD because it is known to cause oxidative stress and damage to many organs in the body. However findings are inconsistent with some studies indicating increased risk while others indicated reduced risk.[61, 68-74] A recent systematic review and meta-analysis showed that heavy alcohol consumption was associated with an increased risk of early AMD whereas the association between heavy alcohol consumption and risk of late AMD was inconclusive. [75]

It is unlikely that alcohol consumption is an important risk factor for AMD.

### 6.2.3 Diet and nutrition

#### Antioxidant nutrients

The "free-radical" theory of ageing proposes that oxygen radicals damage cells over time.[76] It is thought that the retina may be particularly vulnerable to oxidative stress because of a combination of exposure to visible light and high oxygen concentrations.[77] Considerable interest has focused on whether foods high in antioxidant micronutrients may be protective for the development of AMD. Carotenoids (in particular beta-carotene, lutein and zeaxanthin), vitamin C, vitamin E and zinc are all common in the diet and have antioxidant properties.

A number of studies have investigated the relationship between dietary intake [78-91] or serum levels[92-97] of antioxidant nutrients and risk of AMD with inconsistent results. Difficulties with interpreting these studies include the fact that people with diets rich in antioxidants are different from people with diets that are low in antioxidants. A recent systematic review of prospective studies of dietary intake found no evidence that diets high in antioxidant vitamins protect against AMD. [98]

Two systematic reviews of the controlled trials of vitamin supplementation undertaken in this area are available.[99, 100] Three large trials provide no evidence to support the hypothesis that supplementation with high dose beta- carotene or high dose vitamin E prevents AMD in the general population.

Eight trials were identified of antioxidant supplementation in people with AMD. The majority of participants were from one trial – the Age-Related Eye Disease Study (AREDS) - which found a reduced risk of progression to advanced AMD in participants with signs of AMD (extensive intermediate size drusen, one or more large drusen, noncentral geographic atrophy in one or both eyes, or advanced AMD or vision loss due to AMD in one eye) who took antioxidant supplements (beta-carotene, vitamin C, vitamin E and high-dose zinc). [101]

Although generally regarded as safe, antioxidant supplements can have adverse effects. Two large trials have shown that smokers who take beta-carotene may be at increased risk of lung cancer.[102,103] The Heart Outcomes Prevention Evaluation (HOPE) Study found that vitamin E supplementation was associated with an increased risk of heart failure in people with diabetes or vascular disease.[104]

#### Polyunsaturated fatty acids

There are two groups of polyunsaturated fatty acids: omega-3 fatty acids and omega-6 fatty acids. The retina contains high levels of the omega-3 fatty acid docosahexaenoic acid (DHA), particularly in the disc membranes of the photoreceptors. The omega-3 fatty acid eicosapentaenoic acid (EPA) has beneficial effects on inflammation which is also implicated in the pathogenesis of AMD.

A recent systematic review identified nine relevant studies of dietary intake of omega-3 fatty acids and AMD.[105] A high dietary intake of omega-3 fatty acids was associated with a 38% reduction in the risk of late AMD (pooled odds ratio [OR], 0.62; 95% CI 0.48 to 0.82). Fish intake at least twice a week was associated with a reduced risk of both early AMD (pooled OR, 0.76; 95% CI, 0.64 to 0.90) and late AMD (pooled OR, 0.67; 95% CI, 0.53 to 0.85). This is promising but not conclusive evidence of a role as there are as yet no randomised controlled trials published on this topic.

The AREDS 2 trial (see section 4.3.1.4 above) is investigating supplementation with omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) (DHA and EPA) (http://www.nei.nih.gov/neitrials/viewStudyWeb.aspx?id=120, accessed 15/2/2007) [56]

Including oily fish in the diet is currently advised for other health reasons and may reduce the risk of developing AMD.

### 6.2.4 Obesity

Measures of obesity such as body mass index (BMI), waist circumference and waist-hip ratio have been measured in a number of studies. In general, reported findings suggest an increased risk of AMD with increasing BMI and abdominal obesity.[106-108] In the AREDS study high BMI was associated with neovascular disease at baseline [109] but this association was not seen with follow up except with GA.[110] Two studies have found evidence of a J-shaped curve and suggested that people with low BMI are also at risk.[111,112] Inconsistencies in relationships have been found and in one study BMI and waist-hip ratio were associated with AMD in women but not men [113] and in another study high BMI was associated with AMD in men and not women.[114]

A recent review concluded that current research has not identified a consistent association between obesity and risk of age-related maculopathy.[115]

## 6.3 Medical risk factors

### 6.3.1 Hypertension

Hypertension may increase the risk of AMD due to its effects on the choroidal circulation.[116] Raised blood pressure has been associated with AMD in some [117-122] but not all [123-125] studies. There is no evidence that antihypertensive medication or treatments to lower blood pressure can prevent the development or progression of the disease.

### 6.3.2 Coronary and vascular disease

People with AMD may be at increased risk of coronary heart disease [121,126], stroke [127] and cardiovascular mortality.[128,129] However, findings have been

inconsistent: and some studies have found no association between history of cardiovascular disease and AMD [119,123,130].

HMG CoA Reductase Inhibitors (statins) protect against cardiovascular disease by reducing dyslipidaemia [131]. Some studies have suggested that people taking statins are at reduced risk of AMD [132-135] while others have not [136-138]

A recent meta-analysis of observational studies concluded that lipid-lowering agents, including statins, do not appear to lower the risk of developing AMD. [139]

### 6.3.3 Diabetes

Diabetes and AMD appear to be unrelated. Many studies have investigated this relationship but few studies have found any link [140]

## 6.4 Genetic risk factors for AMD

Multiple genetic risk factors have been described for AMD and have been reviewed recently [141]. Some of these are relatively rare, contributing genetic risk of small effect to a low number of patients. However, unlike other common diseases, AMD is relatively unusual in that several genes of large effect have been reported to affect a large fraction of patients. This is encouraging as it suggests that in the future, screening programs or gene-dependent treatments will be feasible as only a small number of genetic polymorphisms need to be assessed to identify genetic risk in a large number of patients.

### 6.4.1 Major genetic risk factors

#### 1) Genes associated with the complement cascade

The complement system is a powerful component of innate immunity which recognizes and facilitates the elimination of pathogens and unwanted host material. Since complement activity can also lead to host tissue injury and inflammation, strict regulation of the complement cascade is important. It is now recognised that several genes which code for proteins involved in the complement cascade either significantly increase the risk of AMD (variation in complement factor H (CFH) and complement component 3 (C3)) or decrease the risk of AMD (variation in complement component 2 (C2) and factor B (BF) and deletion of CFH-related genes CFHR1 and CFHR3).
In 2005 it was established that a mutation in a key regulator of the complement pathway: complement factor H (CFH) is strongly associated with risk of AMD [142-144.] Carriage of the Y402H polymorphism in this gene increases the risk of developing AMD between 2 and 7 fold [142-144] and accounts for up to 50 % of the population attributable risk of AMD. Identification of this association with AMD has re-defined AMD as a disease of complement dysregulation in roughly 50 % of patients.
More recently variation in C3 has been shown to increase the risk of developing AMD up to 2.6 fold [145.] In addition there is a protective deletion of CFHR1 and

CFHR3 occurring close to the CFH locus in 8 % of AMD patients[146] and a protective haplotype, reducing risk of AMD is associated with variation in complement factors C2 and factor B.[147]

### 2) Chromosome 10q locus

Single nucleotides polymorphisms (SNPs) in chromosome 10q26 are associated with an increased risk for AMD. However it is currently unresolved whether SNPs identified in the coding region of the LOC387715/ARMS2 (age-related maculopathy susceptibility 2) gene [148], or located in the promoter region of HTRA1 (high temperature requirement factor A1) [149,150] represent the true genetic risk variant at this locus. As these SNPS exist in strong linkage disequilibrium, further functional studies are needed to confirm which is the true genetic variant. What is clear is that a major genetic risk factor for AMD occurs at this 10q26 locus with an up to 10 fold increased risk of developing AMD.[149]

### 3) Other major genetic loci

Meta-analysis of whole genome linkage studies identified several significant genetic loci for AMD.[151] These are on chromosomes 1 (CFH locus), and 10q (discussed above) but also 1q, 2p, 3p and 16 where undiscovered genetic variants are yet to be revealed.

## 6.4.2 Gene-environment interactions

It has been shown that there is a synergistic effect between smoking and carriage of a genetic risk factor at the AMD 10q26 locus.[152] If patients carry this genetic risk factor, the association of AMD and smoking is shown to be approximately three times stronger.[152]

## 6.4.3 Pharmacogenetic relationships

Some preliminary pharmacogenetic relationships have been reported e.g. Patients carrying the CFH Y402H CC genotype have been to shown to develop greater visual acuity loss after photodynamic therapy (PDT).[153] In addition patients with the CFH Y402H CC genotype fared significantly worse after intravitreal Bevacizumab injections than did those with the CFH TC or TT genotypes.[154] Together, these studies suggest that potential pharmacogenetic relationships exist between the genetic risk factors associated with AMD and response to treatment. If true, these pharmacogenetic associations could be exploited to create a biomarker profile to help guide treatment algorithms for the management of wet AMD. There is also evidence that carriage of CFH or HTRA1 genetic variants can increase the risk of developing CNV or alter the phenotype of CNV.[155-161]

AMD is unusual among common diseases (such as diabetes, breast cancer etc) in that a relatively small number of genes of large effect have been identified. Several of these alter the alternative complement pathway and so drugs which

inhibit complement activation may represent a novel method of treatment in the future. Preliminary pharmacogenetic studies suggest that knowledge of a patient's genetic risk factors for AMD may result in personalised medicine where patients with different genotypes are offered different treatments in the future.

## 6.5 Others

### 6.5.1 Cataract Surgery and Macular Degeneration

The relationship between cataract surgery and the subsequent development of age-related macular degeneration (AMD) is controversial.[162-172] Some studies have shown an association between the presence of cataract and late AMD suggesting that cataract and late AMD share common pathological pathways. There are also reports in the literature showing an increased risk of AMD following cataract surgery. The Beaver Dam and Blue Mountains Eye Studies pooled data for longitudinal analysis of risk factors and found that cataract surgery was a consistent risk factor for the development of neovascular AMD. [163] Studies have also shown that patients with a mild to moderate degree of AMD and moderate / severe cataract will benefit from surgery.[164,165] As the relationship between cataract and surgery for cataract with AMD is unclear, additional long terms observational cohort studies are required. The use of OCT prior to and following surgery may be useful to rule out any subtle pre-existing neovascularisation that may be difficult to pick up in cataractous eyes. It is also prudent to warn patients that the visual prognosis is guarded if signs of AMD are present in the macula.

### 6.5.2 Sunlight Exposure and Macular Degeneration

The relationship between sunlight exposure and macular degeneration is not clear cut. Different wavelengths of light can penetrate the eye to different degrees with UV radiation mainly being absorbed or deflected by the lens and cornea. There is good laboratory evidence that exposure of the macula to blue wavelengths of light can lead to changes similar to macular degeneration. [173] There is also evidence to suggest that high levels of pigment in the form of lutein and zeaxanthin which absorb blue light has a protective effect on the development of macular degeneration but translating this information into clinical studies is more difficult. [174]

The best way to accurately estimate total light exposure would be in the form of a prospective cohort based study but this is not possible given the length of time patients would be required to be followed up. Cross- sectional and population based studies have lead to inconsistent findings in terms of the relationship between light exposure and the subsequent development of AMD. [175-177]

Despite conflicting results it would seem prudent to advise sunglasses with 100% protection against UVA and UVB radiation in bright environments. Sunglasses

provide roughly 50% more UV-blue photoprotection than either violet or blue blocking intraocular lenses.[178] More information/evidence for a protective effect of blue blocking lenses in the context of early AMD, and development of AMD is required.

### 6.5.3 Gender/sex hormones

A higher prevalence of AMD in women has been reported but much of this increased risk can be attributed to increased longevity.[179] Conversely, the association between vascular disease and AMD has lead to the hypothesis that exposure to oestrogen (either endogenous or exogenous) might lead to a reduced risk of AMD in women.

Markers of exposure to oestrogen in women, such as age at menarche and menopause and use of hormone replacement therapy are inconsistently associated with AMD.[180-190]

In one randomised controlled trial [191] the Women's Health Initiative study randomised women to conjugated equine oestrogens (CEE), CEE with progestin (CEE+P) or to placebo. Over 4,000 women aged 65 years and above in this trial were evaluated for the presence of AMD after an average of 5 years treatment. Overall there was no association between oestrogen supplementation and development of AMD. The group treated with CEE+P had a reduced risk of one early sign (soft drusen) and also of neovascular AMD however the study was underpowered and the authors were unable to make a definitive statement regarding these effects.

### 6.5.4 Race

There is significant variation in the prevalence of AMD in different racial/ethnic groups.[192,193]

There is a higher prevalence of large drusen, pigmentary abnormalities, neovascular AMD and geographic atrophy in white people compared with black people.[194-198] Some studies have reported a lower prevalence of AMD in Hispanic people [199-201] but similar prevalence of early signs of the disease.[199,200]

### 6.5.5 Educational status/social class

A number of studies have suggested that increasing years of education are associated with a decreased risk of AMD.[186,199,200] However strong trends were not observed in these studies and several studies have found no association.[204, 205] It is unlikely that socioeconomic status is an important factor determining the distribution of AMD in the population.

**Practical Points**

**Smoking is the most consistent risk factor for the development of late AMD. Patients should be advised on cessation of smoking. Posters with a clear message on smoking cessation with a helpline number are available from the College website http://www.rcophth.ac.uk/docs/college/patientinfo/SmokingBlindnessPoster.pdf**

**The AREDS formulation for prevention of progression to late AMD is not recommended in smokers or those who have recently quit smoking as beta- carotene which is contained in this formulation has been associated with an increased risk of lung cancer.**

## 7 Natural history of vision loss

The onset of GA or CNV results in progressive and unremitting loss of central vision in the affected eye. A number of studies have shown that extrafoveal CNV will grow towards the fovea. Once foveal involvement has occurred CNV will expand and involve ever increasing areas of the macular retina. Thus the majority of eyes will experience moderate (defined as a doubling of the visual angle which equates to a 3 line worsening on the ETDRS visual acuity chart) or severe vision loss (defined as a quadrupling of the visual angle and which equates to a 6 line worsening on the ETDRS chart).

### 7.1 Natural history of visual acuity outcomes without treatment

Eyes with only drusen typically do not suffer overt vision loss. Occasionally such eyes may manifest subtle changes in visual function but mostly patients are unaware of any change. Distortion can be reported by patients with large soft drusen with related focal pigment epithelial detachments and patients with geographic atrophy, although much more commonly in patients with exudative AMD. Many investigators have shown subtle changes in acuity, contrast sensitivity, colour vision, dark adaptation and scotopic sensitivity in eyes with early features of AMD.[206, 207,208] GA is associated with severe central visual decline. A longitudinal study of GA found that 31 % suffered a 3-line loss in acuity within 2 years of diagnosis and that this had increased to 53% at four years.[209, 210] Once neovascularisation has supervened, the natural history is one of acute central visual disturbance followed by unremitting vision loss.[211, 212] Over a period of time which is generally variable, relative scotomata become absolute. Some patients with a fellow eye with good vision will not notice any such changes despite the onset of neovascularisation. [213] Guyer et al reported the visual acuity loss associated with subfoveal CNV and an initial visual acuity of 20/100 (6/30, 0.7logMAR) or better, 77% had lost 4 lines of vision by 24 months and 64% 6

lines. They also reported that increased size of CNV at baseline is associated with a decreased initial visual acuity.[212]

In the Macular Photocoagulation Study randomised controlled trials for laser photocoagulation the primary outcome was distance visual acuity. The natural history of untreated eyes from the control groups of these trials shows a massive loss of vision. The trials investigated extrafoveal, juxtafoveal and subfoveal membranes.

In the subfoveal new CNV study, 1.9 lines of vision were lost in the first three months, 4.4 lines at 24 months and 5.5 lines at 48 months. [214,215] In the subfoveal recurrent CNV study 1.7 lines were lost from baseline to 3 months, 3.4 lines from baseline to 24 months and 3.9 lines after 36 months. [216,217]

Table 1 (below) shows the proportion of eyes in each group to experience severe visual loss (≥6 lines) from baseline to each subsequent visit.[215, 218,219] The proportions are relatively similar for each location of CNV studied.

| Study (Number at Baseline) | **3 M** | **6 M** | **12 M** | **24 M** | **36 M** | **48 M** |
|---|---|---|---|---|---|---|
| Extrafoveal (N=117) | 0.10 | 0.29 | 0.41 | 0.56 | 0.63 | 0.65 |
| Juxtafoveal (N=249) | 0.13 | 0.28 | 0.45 | 0.54 | 0.61 | 0.63 |
| Subfoveal recurrent (N=114) | 0.11 | 0.19 | 0.29 | 0.38 | 0.39 | |
| Subfoveal new (N=183) | 0.11 | 0.18 | 0.30 | 0.39 | 0.38 | 0.45 |

**Table 1:** The proportion of eyes losing at least 6 lines of vision distance visual acuity (DVA) from baseline to each follow up visit in the observational groups of the MPS clinical trials

Mean visual acuity of the placebo group in the Treatment of AMD with Photodynamic Therapy (TAP) study was 20/80 (0.6 logMAR) at baseline. By 3 months this had reduced to 20/126 (0.8 logMAR) and by 12 months to 20/200 (1.0 logMAR). Mean visual acuity was 20/200 at 24-month follow up as well.[220,221]

In the Verteporfin In Photodynamic Therapy (VIP) study, mean baseline visual acuity was 20/100 (0.7 logMAR). By 12 months, mean acuity had reduced to 20/126 (0.8 logMAR) and at 24 months reduction to 20/200 (1.0 logMAR) had occurred. [222]

The most robust information on natural history comes from interventional controlled clinical trials which have included a placebo or control arm. A recent

meta-analysis of all existing data has shown there is a steady decrease in visual acuity.[223] The mean VA change in logMAR progressed from 0.1(1 line lost) at 3 months to 0.3 (2.7 lines lost) after 12 months and 0.4 (4 lines lost) after 24 months. The proportion of patients who developed severe vision loss (>6 lines) from baseline increased from 21.3% at 6 months to 41.9% by 3 years. The proportion of patients with VA worse than logMAR 1.0 (20/200 Snellen) increased from 19.7% at baseline to 75.7% by 3 years. [223]

### 7.2 Lesion morphology and vision loss

While a number of studies have examined the visual function of eyes with early AMD, the relationships between visual function and more advanced AMD lesions have not been systematically investigated.[206,207,224] The treatment and control groups of clinical trials such as the MPS have shown that a wide range of visual function is possible. It has been shown that a large number of eyes with large lesions have good visual acuity and that some with small lesions have poor visual acuity.[225] AMD does not appear to be a single cohesive morphological entity and therefore it is not surprising that there is inconsistency between the severity of retinal changes and visual function.[225, 226] Various macular lesion characteristics have been shown to influence vision. These include in the first instance the nature of pathology, where the exudative stages have been shown to cause much more loss of visual acuity as compared to those with, atrophic stages.[227] Secondly the location of the lesion, patients with subfoveal lesions and those with posterior edges extending towards the fovea tending to have poorer vision.[211,228] Finally the extent of the lesion and the components of the lesion influence vision, where subretinal scars result in worse acuity than lesions without fibrosis. [209,211] A study by Hogg et al has also shown that fibrosis, when present within the fovea, results in notably worse visual acuity when compared with fibrosis at an extrafoveal location.[229] The extent of lesion or lesion components were also found to affect vision, with larger areas of atrophy and fibrosis adversely influencing clinical measures of vision. Blood and exudate also had an adverse effect on vision but to a lesser extent. Lesions exhibiting pigmentation, subretinal fluid and CNV were found to have acuity that was no worse than lesions without these components.[229]
In a study of 93 patients with subfoveal CNV, the status of the better or worse seeing eye was found to influence visual acuity. In better seeing eyes, the correlation between the classic component and contrast sensitivity was significant and in worse seeing eyes, the total lesion size was significantly correlated with resolution and contrast. The distance between the fovea and healthy retina was also significant for predicting visual function.[230]

### Practical Points

**Left untreated CNV will progress to involve the foveal avascular zone in the majority of eyes leading to moderate or severe visual loss.**

## 7.3 Contrast Sensitivity

Limitations associated with the assessment of conventional high contrast visual acuity measurements have been highlighted for over 40 years.[231]

These limitations hinge on the fact that much of what we require our visual system to do involves the identification of detail within a low contrast world, as opposed to the assessment of spatial resolution under conditions of very high contrast. Traditionally, and within the laboratory setting, contrast sensitivity has been measured using computer generated sinusoidal grating patterns on high quality oscilloscopes.[231] Testing, using psychophysical techniques of this nature, is however expensive, time consuming and impractical within the busy clinical setting. Paper or "hard copy" screening tests designed using sinusoidal gratings were subsequently developed and, of these, the most well known are the Cambridge Low Contrast Grating Cards[232], Arden Gratings[233] and the Vistech (VCTS) Charts.[234] None of these tests have been used extensively within (NHS) clinical settings, one reason being that clinicians would appear to have an inherent preference for tests incorporating optotypes.

Of the clinical tests which have subsequently been developed to help overcome this problem, the most widely known is the Pelli-Robson chart.[235] This test, which is essentially now recognised as the "gold standard" against which other optotype based CS tests are judged, utilises triplets of letters decreasing in contrast by a factor of $1/\sqrt{2}$ from top to bottom. Alternative optotype based charts are the "MARS letter contrast sensitivity chart", on which successive letters decrease in contrast by 0.04 Log Units[236], and a series of charts, produced to mimic high contrast logarithmically designed acuity charts but on which letters are printed at designated low contrast values. These charts include the "Ragen Low Contrast Letter Charts"[237], the "Bailey Lovie Reduced Contrast Chart" [238] and the "Lea Low Contrast Symbol Charts".[239]

Comparison of data acquired using different tests is difficult and often inappropriate as the design principles differ. Tests such as the Pelli-Robson assesses contrast sensitivity at a single spatial frequency near the peak of the CS curve whereas those like the Bailey-Lovie chart test acuity or spatial resolution at a specified level of reduced contrast.[240]

There is, however, considerable evidence to suggest that reduction in contrast sensitivity and low contrast acuity can be a predictor of impaired performance, particularly in relation to those tasks that involve driving [240], mobility [241,242], postural stability [243], face recognition [244] and reading speed.[245-247]

In the US, the National Research Council now recommends that CS be used as a basis for disability determination on the Social Security Programme.[248]

In studies on ageing, visual acuity has been found to have deteriorated by a factor of 2.4 times in those over the age of 90 years, compared to that of younger observers in their 50s. The deterioration of low contrast acuity, in the presence of glare, has however been shown to decrease by a factor of 18 times.[249] Significant deterioration of low contrast acuity has, in addition, been shown to begin to deteriorate approximately 12 years earlier than high contrast acuity.

Against this background, it has been suggested that low contrast acuity measures could be predictors of subsequent high contrast acuity loss [250]. Most studies do, however, show a moderate correlation between measures of VA and contrast sensitivity with Rubin et al suggesting that a 6 letter loss of CS on the Pelli Robson chart has a similar impact on self reported visual disability as a 15 letter loss (3 lines) on a high contrast LogMAR acuity chart.[251]

Studies designed to evaluate the impact of ARMD on contrast sensitivity and the relationship between CS, VA and functional vision, in this condition, are not easy to interpret. In a study of patients enrolled for radiation therapy of macular neovascular membranes, contrast sensitivity measurements could not be used consistently to predict similar rates of progression.[252] Kleiner at al, using Ragen Letter Charts, found that when comparing CS in a group of patients (n=15) with macular drusen to that from a group of age matched norms (n=27) all with an acuity of at least 20/20, those with drusen showed a greater reduction in the number of letters read as target contrast decreased.[253] Stangos et al found that the CS loss in eyes with drusen was most significant at mid and high spatial frequencies.[254] Brown et al also found CS loss to be greatest at high spatial frequencies and that these findings were unrelated to the degree of retinal eccentricity.[255] Alexander et al, although finding a significant correlation between CS loss and decreased VA in a range of patients with early to late ARMD, noted that there was considerable disparity at all acuity levels.[256] In a study involving 209 patients with either unilateral or bilateral ARMD, Bansback et al found contrast sensitivity to be a significant independent predictor of health related QOL and health utility.[257] Attempts to correlate the composition and location of macular lesions in cases of choroidal neovascularisation have shown that the strongest correlation is between lesion size and CS (r=0.52) and that the relationship is strongest when the lesion was predominantly classic.[258] Results recorded under conditions of varying luminance have also been reviewed, the conclusion being that adaptation systems which enable patients to detect both high and low contrast detail are impacted by AMD.[259] Suness et al (2008) have, in particular, shown low luminance deficit (LLD) to be a strong predictor of subsequent VA loss in a cohort of 91 patients with geographic atrophy, followed over a 2 year period.[260]

## 7.4 Near Vision and Reading Speed

In addition to acuity and contrast other tests of macular function include near acuity and reading speed.[261] Threshold near acuity is determined first and then reading speed (number of words read per minute is recorded either at the threshold acuity or using words just larger than reading speed).[261,262] The Macular Photocoagulation Study was the first clinical trial to use reading speed as an outcome measure. [215] Since then very few studies have used near acuity and reading speed [262, 263] as an outcome measure most likely because these tests take considerable length of time to undertake. Although distance VA remains the most popular outcome measure, recent work on health related quality of life shows that near acuity and reading speed exhibit correlations with self reported visual functioning that are not explained by visual acuity alone. [264]

## 7.5 Self reported visual functioning and quality of life

The term “quality-of-life” (QoL) is used to represent several distinct concepts. These include physical functioning (health status), functional status (ability to participate in daily activities) social functioning (interactions and relationships) and psychological functioning (satisfaction and well-being). In addition, QoL can be evaluated with generic scales or disease-specific questionnaires. It is widely agreed that vision-specific instruments provide more sensitive measures of the impact of AMD on QoL.

Several comprehensive reviews of QoL instruments have been published since 2000. [265-268] Of the 25+ vision-specific QoL instruments, only three were specifically developed to assess patients with AMD (the MacDQoL, DLTV, and MLVQ). However several of the other popular questionnaires have been validated in patients with AMD (VF-14, ADVS, NEI-VFQ) or in low vision patients, most of whom had AMD (MAI, VQoL). Validation of QoL questionnaires for AMD has mostly followed the traditional methodology which includes principal components analysis and measures of internal consistency reliability to reveal the underlying dimensionality of the instrument, and correlation with clinical vision tests (e.g. acuity or contrast sensitivity) as an indicator of construct validity. But recently there has been a shift towards the use of item-response theory, in particular Rasch analysis, to validate questionnaires.[269] Rasch analysis offers several distinct advantages over the traditional approach [270]: ordinal measures are converted into a linear interval scale which is more amenable to conventional parametric statistics, missing responses are easily accommodated, the questionnaire can be efficiently targeted to the functional level of the patient sample, and data can be compared across different questionnaires. [271]

Space doesn’t allow for a comprehensive review of QoL outcomes in AMD. Instead, we highlight some of the key findings, emphasising treatment studies that included a control group. Few vision-specific instruments attempt to measure

the full spectrum of QoL, with the possible exception of the MacDQoL. The greatest emphasis in studies to date has been on physical function – the ability to participate in visually demanding activities such as reading the newspaper or recognizing a face from across the room. Neither the Macular Photocoagulation study nor the Photodynamic Therapy study reported QoL outcome data. The Sub Macular Surgery Trail failed to show any difference between treatment and controls using the NEI-VFQ [272] as did the Sub-Foveal Radiotherapy Study, using the DLTV. [273]Anti-VEGF treatments including ranibizumab (Lucentis) [274] and pegaptanib sodium (Macugen) [275] both showed significant improvements in QoL measured with the NEI-VFQ. The provision of low vision services improved functional ability compared to no intervention (LVQOL) [276] and a self-management training course improved self-efficacy compared to waiting list controls.[277] However, a comparison of standard hospital-based low vision service to an enhanced multi-disciplinary service found no difference in QoL (VCM1) after 12 months.

One controversial issue in the assessment of QoL is the determination of utility values. Utility values measure the desirability of health states and are used in economic analysis of cost-effectiveness of various treatment options. Considerable work has been done to develop reliable methods for assessing utility values based on patient preferences. The most common method – the time tradeoff (TTO) – determines how many years of remaining life expectancy a patient would trade in return for a guarantee of perfect health (vision). TTO utilities have been linked to visual acuity in the better eye. [278] In fact, most of the evaluations of cost-effectiveness of treatments for AMD have been based *solely* on better eye acuity. However, it has been shown that acuity in the worse eye also influences QoL.[279] Moreover, other dimensions of visual function – such as contrast sensitivity and visual fields – independently affect QoL. In one study of patients with AMD, contrast sensitivity had the dominant effect. [280] Finally, other methods based on patient preferences, such as conjoint analysis [281] do not yield utility values that are equivalent to TTO, nor are they as closely related to visual acuity.

## 8 Therapies for acute neovascular AMD

This section is concerned with the evidence for current and emerging therapies for choroidal neovascularisation (CNV) secondary to AMD, which is an area of rapid development. It will mainly concentrate upon evidence that has been published in peer-reviewed journals.

### 8.1 Laser photocoagulation

The Macular Photocoagulation Study Group (**MPSG**) undertook a series of randomised, controlled trials assessing photocoagulation treatment for CNV. The object of the treatment was to destroy the neovascular complex with heavy confluent laser, and thereby try to reduce further loss of vision resulting from its

further enlargement and/or ongoing leakage. Lesions were classified as extrafoveal if 200μm or more from centre of the foveal avascular zone (FAZ), juxtafoveal if they were 1-199μm from the centre of the FAZ, or subfoveal.

### 8.1.1 Extrafoveal lesions.

This MPS trial was carried out using argon laser before differentiation of angiographic patterns into classic or occult was recognised. Well-defined extrafoveal lesions were included with a baseline vision of 20/200 or better. Lesions were treated with heavy confluent laser, with 100 μm margin beyond the lesion resulting in an absolute scotoma within the area of treatment. At 5 year follow-up, 64% of untreated vs. 46% of treated eyes had progressed to severe visual loss. Recurrences were common, and were seen in 54% of treated eyes at 5 year follow-up.[282] Another prospective clinical trial in the UK reached similar conclusions.[283]

### 8.1.2 Juxtafoveal lesions

In this MPS trial krypton laser was used for lesions that were up to 199 μm from the centre of the FAZ, or CNV 200 μm or further from the FAZ with blood or blocked fluorescence extending within 200 μm of the centre of the FAZ. Lesions were treated with 100 μm margin, or 100 μm into the blood or until the centre of the FAZ. At 3 year follow-up 49% of treated eyes compared to 58% untreated eyes had lost six or more lines of visual acuity. Most of the visual loss in both groups occurred within the first few months after randomisation. In addition, more than twice as many treated patients as untreated patients retained visual acuity of 20/40 or better.[284] Persistent CNV, defined as leakage detected during the first 6 weeks after laser treatment, was present in 32% of eyes compared to only 10% in the extrafoveal argon study. There was a 50% recurrence rate at 2 year follow-up. [285,286]
One of the newer treatment options (see below) would now be considered if a juxtafoveal lesion could not be completely treated without involving the central fovea.

### 8.1.3 Subfoveal lesions

Two trials were undertaken to assess the effectiveness of laser treatment in eyes with subfoveal CNV. [287,288] One trial evaluated the effectiveness of laser photocoagulation of subfoveal lesions without previous treatment, in which there was a component of classic and the whole lesion was well-demarcated. Baseline vision was between 20/40 and 20/320 and the lesions included in the trial were no larger than 3.5 disc areas in size. There was an initial reduction of vision of approximately 3 lines, but by 2 years the vision had dropped more than 6 lines in 37% of untreated vs. 20% of treated eyes. By 4 year follow-up 30% of treated eyes vs. 60% of untreated eyes were 20/400 or worse. Eyes with smaller lesions and poorer acuity seemed to benefit most from treatment. A second trial

evaluated results of treating recurrent extra/juxtafoveal lesions with subfoveal extension and also showed significant benefit compared to no treatment.

Since the advent of newer and better treatments, photocoagulation of subfoveal lesions is rarely indicated, but might be considered for small subfoveal lesions where the visual acuity is too poor to consider other treatment modalities.

**Practical Points**

**Patients undergoing argon laser treatment should have it performed as soon as possible and within a week following fluorescein angiography. Patients should be warned that treatment will produce a permanent scotoma and that they will need monitoring. Recurrences are usually subfoveal and if this happens alternative treatments may be required.**

**Patients should be examined 2 weeks following laser to confirm obliteration of the CNV and fluorescein angiography performed. Patients should be reviewed 4- 6 weeks later and thereafter depending on clinical findings.**

**The majority of CNV recurrences after photocoagulation occur in the first year.**

### 8.2 Photodynamic therapy with Verteporfin

This is a procedure whereby the photosensitising dye Verteporfin (Visudyne, Novartis) is given intravenously. Verteporfin is taken up selectively by rapidly proliferating endothelial cells which have greater LDL receptor expression. This is followed by the delivery of laser light of a wavelength of 689 nm to the CNV lesion as a single spot with a diameter 1000 μm larger than the greatest linear diameter of the lesion. The energy from the laser is taken up by the Verteporfin, and this leads to damage to vascular endothelial cells and thrombotic occlusion of the blood vessels within the CNV lesion. The major advantage of this approach over laser photocoagulation is that there is minimal damage to the overlying retina. [289,290]
The Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study showed that there was a decreased risk of moderate visual loss (decrease in three or more lines) or severe visual loss (decrease in six or more lines) compared to natural history in eyes with predominantly classic lesions on fluorescein angiography. [291,292,293]
Of these patients 59% of the Verteporfin treated group lost less than 3 lines of vision at two years compared with 31% in the placebo-treated group. This treatment benefit was maintained at five year follow-up.[294] The results were even better in the absence of occult disease. Treatment also showed benefit in terms of contrast sensitivity.

PDT was also initially found to have a treatment effect for certain types of occult disease with no classic component. An analysis of patients with occult with no classic CNV showed that PDT was effective in reducing visual loss in patients with either small lesions (4 disc areas or less) or lower levels of visual acuity (Snellen equivalent of 20/50 or less).[295,296] However a further study Visudyne in Occult Choroidal Neovascularisation [VIO] study of occult CNV did not reveal any benefit therefore the EMEA has withdrawn the European license for PDT in occult CNV.[297] PDT is therefore no longer recommended for occult CNV.
Whilst minimally classic lesions evaluated within the TAP study showed no benefit from treatment, subsequent retrospective analyses of relatively small (4 disc areas or less) minimally classic lesions did show some benefit from treatment.[296] In the Visudyne in Minimally Classic Neovascularisation **(VIM)** study, minimally classic lesions that were 6 disc areas or less did show a reduction in moderate visual loss and reduced conversion to classic disease compared to placebo that was statistically significant only when reduced light energy was used.[298]

PDT is very well tolerated, but may occasionally give rise to visual loss. In the TAP study loss of more than 4 lines of vision occurred in 0.7% of patients in the TAP study and 4.4% of patients in the VIP study. All patients will be photosensitive for 2 days after treatment.

**Practical Points**

**PDT should be performed within 1-2 weeks of the initial fluorescein angiogram and then as required 3 monthly. It is recommended only in patients with classic and predominantly classic lesions.**

**It should be clearly explained to patients that treatment with PDT will reduce the risk of moderate and severe visual loss but that most patients will still lose vision and visual improvements are unusual.**

**Severe vision loss can occur immediately after treatment in 1-4% of patients and this may be permanent in a small proportion of cases.**

**Idiosyncratic back pain occurs in 1-2% of patients which resolves when the infusion is stopped.**

**Patients should be advised to avoid direct sunlight exposure for 2 days following treatment.**

### 8.2.1 Combined Verteporfin PDT and triamcinolone

Several small studies have shown that Verteporfin PDT combined with intravitreal triamcinolone acetate (IVTA) may improve the outcome of standard verteporfin PDT, and reduce the number of retreatments.[300-307]
The Verteporfin Intravitreal Triamcinalone Acetonide Study (VERITAS) trial which looked at PDT together with either intravitreal injections of Macugen (n= 38) or 1mg (n= 32) or 4mg of triamcinalone (n=41) was stopped after 6 months of follow-up as there were no significant difference between groups in terms of loss of 15 letters on the visual acuity test which was the planned primary endpoint of the study (unpublished data presented at ARVO 2007).[308]
Any potential benefits of intravitreal triamcinalone must be weighted against the potential complications of treatment that include cataract progression, increased intraocular pressure and the risk of endophthalmitis per injection. [309-310]
Triamcinolone used alone was not shown to be effective at 1 year follow-up. [311]
Combination therapy of PDT verteporfin and periocular triamcinolone injection may be safer but clinical trial evidence of the efficacy is limited and a randomized controlled trial did not find any reduction in the fluorescein leakage 3 months after a single periocular injection of corticosteroid and PDT compared to PDT alone. [312]

**Practical Points**

**To date there is little evidence to support adjunctive use of corticosteroids and PDT**

### 8.3 Surgery

The submacular surgery trials assessed surgery with removal of CNV versus observation for subfoveal CNV that were at least 50% blood and > 3.5 disc areas in size with vision 20/100 or worse. Surgery did not increase the chance of stable or improved visual acuity, and was associated with a high risk of rhegmatogenous retinal detachment, but did reduce the risk of severe vision loss in comparison with observation. [313] There are several case series reporting results of pneumatic displacement of submacular haemorrhage with or without tissue plasminogen activator (tPA), but visual outcomes have been historically poor due to the underlying CNV. [314- 318]
It remains to be seen whether this approach combined with intravitreal anti-VEGF treatment would give improved results. Macular translocation has been shown to significantly improve vision in a proportion of treated cases.[319-324]
NICE assessed the evidence for macular translocation in 2004 and reported that 'the current safety and efficacy data would not support its use without special arrangements for consent, audit and research'.
http://www.nice.org.uk/nicemedia/pdf/IPG048guidance.pdf

## 8.4 Ionising radiation

Radiotherapy can inactivate rapidly proliferating cells, and therefore could be of potential benefit in neovascular AMD by its effect on the capillary endothelium of the CNV. There have been a number of studies assessing radiotherapy for AMD, and some of these have shown a significant benefit from treatment.[325-332] One of the difficulties is determining what is the optimum treatment regime, both in terms of the radiation dose, as well as the mode of delivery. The treatment regimes have varied between different trials. A Cochrane review in 2004 reported no good evidence of benefit from radiotherapy [333] overall and NICE assessed the evidence for its use in 2004, reporting that there was little evidence for efficacy overall and recommended its use only within clinical trials.
http://www.nice.org.uk/nicemedia/pdf/IPG049guidance.pdf- radiotherapy guidance
Newer therapies looking at delivery devices for focal targeted radiotherapy by the intravitreal route are under evaluation, with early promising results.

## 8.5 Anti-angiogenic therapy

### 8.5.1 Pegaptanib sodium (Macugen, Eyetech/Pfizer)

Pegaptanib sodium binds and blocks the activity of isoforms of vascular endothelial growth factor-A (VEGF-A) that contain at least 165 amino acids. VEGF-A is a pro-angiogenic growth factor that also stimulates vascular permeability and is thought to have a major role in the pathology of choroidal neovascularisation. It exists in a number of different isoforms that result from alternative splicing of VEGF-A mRNA. In the VISION study Pegaptanib sodium was given by intravitreal injection at six weekly intervals over two years at doses of 0.3, 1.0 and 3 mg. [334, 335] All lesion types were included but patients with predominantly classic lesions received adjuvant PDT treatment making the results difficult to compare with other monotherapies. The recommended dosage is 0.3 mg as the higher doses in the trial did not show additional benefit. After one year a treatment benefit was seen with all lesion types compared with sham 70% of treated patients lost less than 15 letters of vision compared with 55% among controls ($P<0.001$). The risk of severe visual loss (loss of 30 letters or more) was 22% in the placebo group and 10% in the treated group. The response was not dependent upon lesion type with treated patients losing on average between 6-9 letters of vision irrespective of whether predominantly classic, minimally classic or occult and sham treated controls losing between 13-18 letters. The main side effects that occurred were endophthalmitis (1.3% of patients), traumatic lens injury (0.7%) and retinal detachment (0.6%). Following a modification in the protocol, the per-injection rates of endophthalmitis were reduced in year 2 of the study. No systemic side-effects were observed. A further

analysis explored visual outcomes in more detail, and suggested that earlier lesions may have improved outcomes, but these results need to be interpreted with caution since this was a secondary subgroup analysis of a relatively small number (64) of patients. [336]
Macugen is now licensed in the UK for the treatment of CNV secondary to AMD. Although there have been no direct comparisons of the different anti- VEGF drugs it seems that ranibizumab is the more efficacious of the two products currently approved for the treatment of neovascular AMD.

### 8.5.2 Anecortave acetate (Retaane)

Anecortave acetate (Alcon) is an angiostatic cortisone, but it does not have the ocular complications of many steroids including raised intraocular pressure and cataract. It is administered at an interval of every 6 months by posterior juxtascleral delivery.
Promising results were seen in a phase II study at 12 months. [337] In this study of predominantly classic lesions when 15 mg of Anecortave acetate was administered at an interval of every 6 months 79% of patients lost less than three lines of vision compared to 53% in the sham-treated group (p=0.0323). However, there were some concerns about this study because of a high rate of loss of participants.
A phase III prospective, masked, randomised noninferiority clinical trial study compared Anecortave acetate (15 mg) every 6 months with Verteporfin PDT given every 3 months if there was angiographic leakage. [338] In this study Anecortave acetate failed the non-inferiority endpoint when the efficacy was compared with PDT for treating predominantly classic CNV at 12 months with 45% of Anecortave treated eyes losing fewer than three lines of vision compared to 49% of PDT treated eyes although there was no statistically significant difference between the two endpoints(p=0.43). During the study it became apparent that reflux of the Anecortave acetate after delivery was a problem and a subgroup analysis of patients in whom this was controlled gave a more favourable outcome. No safety problems with Anecortave acetate were detected. The drug is not licenced for use within Europe although it is licensed in Australia. Further studies are underway to assess its role in prophylaxis or in combination with other treatments.

### 8.5.3 Ranibizumab (Lucentis, Genetech Inc/Novartis)

Ranibizumab is a humanised Fab fragment of a monoclonal antibody that binds to and inhibits the action of all isoforms of VEGF-A. Two randomised, controlled, double-blind studies have now been published in which ranibizumab was delivered by intravitreal injection on a 4 weekly basis over two years; the MARINA and ANCHOR studies

In ANCHOR and MARINA two doses of ranibizumab (0.3 and 0.5 mg) were administered. In both studies follow up was for two years but the primary endpoint was the proportion of patients losing less than 15 letters from baseline visual acuity at 12 months.
In the MARINA study eyes with minimally classic or occult CNV were treated with ranibizumab (0.3 mg or 0.5 mg) at monthly intervals or sham injections. [339] At 12 months 94.5% of the group given 0.3 mg of ranibizumab and 94.6 given 0.5mg had lost fewer than 15 letters of vision, compared to 62.2% in the sham injection group. Visual acuity improved by 15 or more letters in 24.8% of the 0.3 mg group and 33.8% of the 0.5mg group compared to 5% in the sham-injection group. The mean visual acuity improved by 6.5 letters in the 0.3 mg group and 7.2 letters in the 0.5mg group but dropped by 10.4 letters in the sham-injection group. All these results were highly significant ($P<0.001$) and were maintained at 24 months.

In the ANCHOR study eyes with predominantly classic CNV were randomized to receive either ranibizumab (0.3 mg or 0.5 mg) with sham PDT treatment or to PDT with sham intravitreal injections. [340] PDT treatments were given at day 0 and then if needed, based on the investigators evaluation. At 12 months 94.3% of the group given 0.3 mg of ranibizumab (and 96.4 % for 0.5mg group) lost fewer than 15 letters of vision, compared to 64.3% in the PDT treated group. Visual acuity improved by 15 or more letters in 35.7% of the 0.3 mg group and 40.3% compared to 5.7% in the PDT treated group. The mean visual acuity improved by 8.5 letters in the 0.3 mg group, 11.3 in 0.5mg group but dropped by 9.5 letters in the PDT treated group. Either dose of ranibizumab produced a highly significant treatment benefit over PDT ($P<0.001$).The 24 month (unpublished results- Macula 2007 Baltimore) have been presented and the findings in terms of loss of fewer than 15 fewer letters or the secondary endpoints of visual gain are similar to the 12 month results.

In both ANCHOR and MARINA the complication rates were similar with presumed endophthalmitis and serious uveitis occurring in 1-2% of patients. While there were no statistically significant differences between the ranibizumab treated arms and the sham or PDT arm in terms of systemic complications, overall more patients treated with ranibizumab experienced non ocular haemorrhages than those in the sham or PDT treated arms.
These studies show that when given on a monthly basis ranibizumab is superior to PDT for predominantly classic lesions and superior to no treatment in minimally classic and occult CNV.

The PIER study evaluated the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with AMD found that the visual gain patients had after the 3 loading injections wasn't maintained by quarterly dosing. At three months the mean changes from baseline VA had been gains of 2.9 and 4.3 letters for the 0.3mg and 0.5 mg respectively. The mean

changes from the baseline visual acuity at 12 months were – 16.3, -1.6 and -0.2 letters for sham, 0.3mg and 0.5 mg groups respectively. [341]
In the PrONTO (Prospective OCT imaging of patients with Neovascular AMD Treated with IntraOcular Lucentis) study ranibizumab was given on an as needed basis after initial stabilisation of the lesion. Results from the PrONTO study suggest that less frequent dosage regimes using OCT parameters to dictate treatment may give equally good visual results. In PrONTO an average of 5.6 injections was used during the year in 40 patients. Patients were only reinjected if central retinal thickness increased by 100 μm, new haemorrhage appeared or visual acuity dropped by 5 letters associated with recurrent fluid on OCT or conversion to a classic lesion. Visual acuity increased by 9.5 letters, better than that reported in the MARINA study in which the mean change in visual acuity was +7.2 letters and slightly less than the ANCHOR study +11.3 letters. The 2-year results of the PrONTO study have been presented ( ARVO 2007) but have not been published. The 2-year follow-up in the PrONTO study was completed by 37 patients, and the reinjection criteria were changed the second year to include any qualitative change by OCT imaging that suggested the reaccumulation of fluid in the macula. This included any change in the retinal thickness, height of a PED, or the reappearance of custs in the retina or sub=retinal fluid. The average number of treatments per year was five, with an average of 9.9 total injections over the 2 years of the study. A mean improvement in visual acuity score was 10.7 letters, with a mean reduction in central retinal thickness on OCT of 215 μm. Baseline vision was maintained by 78% of patients, and improved by 15 letters or more in 43% of patients. [342, 343] Obviously this study contains a small number of patients and larger trials to confirm these findings such as the SAILOR and SUSTAIN study are underway. The SAILOR study is a larger study of 5000 patients with all subtypes of new or recurrent active subfoveal wet AMD evaluating two different doses 0.3mg and 0.5 mg of ranibizumab administered once a month and thereafter on an as needed basis. However, unlike the PrONTO Study which followed patients monthly, the SAILOR Study only required visits every 3 months. The SUSTAIN study follows patients monthly. The results of these studies will provide information on optimum dosage and treatment regimes.

The 0.5mg dose has been licensed for use in the USA, Europe and UK.

### 8.5.4 Bevacizumab (Avastin)

Bevacizumab (Genentech Inc.) is a humanised full-length antibody that is derived from the same monoclonal antibody as ranibizumab, therefore it is likely to recognise the same epitope on all isoforms of VEGF as ranibizumab, but bind with a different affinity. The serum and vitreous half lives of bevacizumab are longer than those of ranibizumab. Bevacizumab was designed for use as a cancer therapeutic and is licensed for intravenous use for bowel cancer.

Whereas ranibizumab is now licensed for AMD in the UK, no applications have been made to license Bevacizumab for the treatment of AMD.
Current data suggesting efficacy of bevacizumab is from small uncontrolled mainly retrospective studies with short-term follow-up. [344-353]
In addition, animal experiments and electrophysiological experimental in humans have not demonstrated early toxicity in the retina. [354] It does appear that bevacizumab can penetrate through all layers of the retina, which initial experiments had suggested would not be the case. Bevacizumab has been used off label in many patients worldwide and it has been suggested that the safety profile is similar to that for Pegaptanib and ranibizumab. [355]
However, to date, there is no data from randomised clinical trials for Bevacizumab. As such there is no systematically collected safety data and the minimum effective dose, optimum dose or dose schedule are unknown. Head-to-head studies to compare ranibizumab and Bevacizumab are being instituted in the UK (IVAN Study) and in the USA (CATT Study).

**Practical Points**

**Pegaptanib and ranibizumab can be used to treat all subfoveal CNV. Although there are no direct comparisons, ranibizumab seems to be the more efficacious of the two.**

**Bevacizumab is unlicensed and its "off –label" status should be clearly stated prior to its use in patients. There are no long-term results on safety and effectiveness of intravitreal bevacizumab.**

## 8.6 Combination Treatments

### 8.6.1 PDT and Ranibizumab

A major limitation of VEGF inhibition therapy is the need for repeated intravitreal injection with its attendant risks of endophthalmitis, retinal detachment and traumatic cataract.

Combination treatments of ranibizumab and PDT have been tried and appear to reduce the need for retreatment but visual results have not been as good as ranibizumab alone. The FOCUS trial of 164 patients with predominantly classic CNVM who were randomised in a 2:1 fashion to receive PDT followed by intravitreal ranibizumab 0.5mg and then monthly ranibizumab or PDT followed by sham injection monthly for 23 months. [356] PDT was performed quarterly in both groups as needed. The study met its primary efficacy endpoint of maintaining or improving vision (defined as a loss of less than 15 letters in visual acuity on ETDRS chart). Results at 12 months showed that over 90 percent of patients (95/105) treated with the combination of PDT and ranibizumab maintained or improved vision compared to approximately 68 percent (38/56) treated with PDT

alone (p<0.0003). This study raised safety concerns over the combination of PDT and ranibizumab as a higher proportion of uveitis was reported in this group. PDT and Lucentis were initially given 7 days apart. The protocol was later amended such that in the remainder of the study, PDT was administered at least 28 days prior to and no sooner than 21 days after administration of Lucentis. The lyophilized formulation of Lucentis used in this study is different from the one used in monotherapy clinical trials like MARINA and ANCHOR.
A further study, PROTECT using the same formulation of ranibizumab as in the MARINA and ANCHOR trials combined with PDT did not raise any safety concerns. This nonrandomized open-label controlled trial of 32 patients found that same day application of PDT and intravitreal ranibizumab followed by three monthly injections improved visual acuity by a mean of 7 letters; 25% of patients improved by > 3 lines by month 4. Retreatments were rarely required during the 9 month follow-up. [357]
Larger trials (the SUMMIT studies) are underway to assess the safety and efficacy of PDT and ranibizumab compared to ranibizumab monotherapy. They consist of the Denali in the US and Canada examining PDT in combination at both standard- and reduced- fluence light doses and Mont Blanc in Europe examining PDT in combination at standard fluence light dose only.

### 8.6.2 Triple therapy- PDT + Anti-VEGF + dexamethasone

Trials are underway looking at triple therapy to treat macular degeneration. The logic behind this is that PDT will eradicate the existing CNV, the steroid will limit the inflammatory response and reduce further upregulation of VEGF and the anti -VEGF will prevent any further angiogenesis. A prospective case series of 104 patients looking at PDT reduced fluence + bevacizumab 1.5mg +dexamethasone 800mcg reported significant and sustained visual acuity improvement after only 1 cycle of treatment. [358]
Larger randomised controlled trials of therapies are warranted and the RADICAL study is looking at the combination of PDT + ranibizumab+ dexamethaone is already underway.

## 8.7 Emerging therapies

Treatments for exudative AMD are developing rapidly. Other methods of VEGF inhibition are being investigated, such as a recombinant VEGF binding protein called VEGF-Trap, receptor tyrosine kinase inhibitors or post-transcriptional silencing of gene expression. Combination therapies and revisiting radiotherapy using in a targeted focal delivery system are also under evaluation. Different modes of drug delivery are also being developed. Therapies that are undergoing investigation for genetically determined retinal disorders may also be applicable for treatment of late AMD.

**Practical Points**

**At present there is insufficient evidence to indicate that combined therapy is better than monotherapy with ranibizumab.**

## 9 Treatment Delivery

As previously indicated, the neovascular lesion in wet AMD leaks fluid causing the separation of tissue compartments and loculation of fluid within the neurosensory retina. These fragile new vessels can rupture leading to accumulation of blood between tissue compartments and within the neurosensory retina. Fibrosis is inevitable causing permanent disruption of tissue architecture. Enlargement of the scotoma with permanent severe vision loss is almost inevitable. As such, treatment must be undertaken without delay and preferably within two weeks of initial development of symptoms or detection of a treatable lesion.

### 9.1 Initiating treatment

It is recommended that a definitive diagnosis of CNV is made prior to initiating treatment. The CNV lesion type, location in relation to the fovea and size of lesion should be established and recorded in the medical notes. Baseline investigations should include best corrected visual acuity, FFA and OCT (Stratus 3 OCT equivalent or higher specification).

Concomitant ocular diseases, along with relevant past medical history need to be documented e.g. IHD, hypertension, diabetes mellitus, although their presence is not a contraindication to treatment. Similarly medication including anticoagulant therapy should be recorded.

The FFA should have a 10 minute run of stereo pairs as in the VPDT Cohort Study Protocol.

Fluorescein angiography may not be possible in patients with poor venous access or considered an unacceptable risk in patients with a past history of fluorescein anaphylaxis or sensitivity.

The OCT should include:

a. Quantitative Fast macular thickness map with default settings; fixation at fovea using the the Stratus OCT or the equivalent scan using the spectral domain OCT technology

b. Qualitative slow scans incorporating all 6 diagonal scans of at least 512 A-scans using the Stratus OCT or the equivalent using spectral domain OCT imaging

Indocyanine green angiography should be considered in patients suspected of retinal angiomatous proliferation and idiopathic polypoidal choroidopathy, to confirm diagnosis. The diagnosis will influence treatment options and prognosis.

### 9.2 Choice of therapy

It is recommended that ophthalmologists with knowledge and experience in the care of patients with age related macular degeneration should initiate treatment and decide upon the type of therapy. The aim of treatment is the improvement or stabilization of visual symptoms. The guiding principle should be that the treatment recommended is in the patient's best interests. The treatment recommendations should be guided by patient characteristics, type of lesion and logistics.

The information included in this section can also be found at http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_-_June_2008.pdf

**Extrafoveal Lesions**

Patients with extrafoveal (posterior edge of lesion located 200 μm from the geometric centre of the fovea) well defined classic CNV may be treated with focal thermal laser photocoagulation as described in the MPS protocol or anti-VEGF therapy if the laser treatment induced scotoma might interfere with normal visual function.

In patients with extrafoveal CNV untreatable by argon laser who are asymptomatic, and where there is no demonstrable progression or threat to vision, observation may be advised.

In patients with large extrafoveal classic or occult CNV with progression, it is justifiable to offer alternative treatments.

**Juxtafoveal Lesions**

As there is a risk that argon laser to a juxtafoveal CNV (lesions with the posterior edge lying between 1 and 199um from the geometric centre of the fovea) will result in severe visual loss owing to proximity to the geometric centre of the fovea, laser photocoagulation is not recommended. Such damage may result from direct foveal photoreceptor and RPE damage, or later encroachment of the scar on the fovea. The patient should be offered alternative retinal sparing therapies.

## Subfoveal Lesions

Following the technology appraisal by NICE, the treatment of choice for lesions with subfoveal involvement is ranibizumab 0.5 mg. Pegaptanib is not recommended by NICE. However, funding for pegaptanib may be sought from Commissioners on an exceptional case basis if there is a documented allergy to ranibizumab, or where the monthly visits are logistically impossible. In addition, where treatment with pegaptanib has resulted in good outcomes previously, such treatment may be continued.
http://www.nice.org.uk/Guidance/TA155/Guidance/pdf/English

Treatment with ranibizumab is indicated when;

1. There is active subfoveal neovascularisation of any lesion type

2. In patients with occult CNV with minimal symptoms or without documented evidence of disease progression a period of observation can be undertaken.

Progression is defined by the presence of at least one of the following criteria:

- The appearance of sight threatening CNV which was not previously suspected or thought to be present.
- Evidence of new haemorrhage and/or subretinal fluid.
- A documented recent visual decline in the presence of CNV.
- An increase in CNV size between visits.

3. BCVA should be equal to or better than Snellen visual acuity > 6/96 (LogMar 1.2 or 24 ETDRS letters).

4. There should be no significant permanent structural damage to the fovea before treatment is commenced. Significant structural damage is defined as longstanding fibrosis or atrophy in the fovea, or a significant chronic disciform scar which, in the opinion of the treating clinician, would prevent the patient from deriving any functional benefit (i.e. prevent further loss of vision) from treatment.

Patients with classic CNV lesions or other lesion types who have failed to respond to other treatment including PDT and laser photocoagulation can be switched to intravitreal injections of anti-VEGF agents.

### Other considerations when commencing treatment

### a) Bilateral active CNV lesions

It is reasonable to treat both eyes of an individual with ranibizumab simultaneously, in the presence of bilateral active subfoveal CNV where the clinical features of each eye falls within the guidelines above. For simultaneous

bilateral intravitreal injections, separate sets of instruments should be used for each eye. Similarly, separate vials of ranibizumab should be used for each eye. The patient should be made aware of the usual cumulative risks of sequential injections either to each eye on separate visits or to both eyes on the same visit.

**b) Predominantly haemorrhagic lesions**

Foveal haemorrhage or haemorrhage of greater than 50% of the total CNV lesion, are not considered reasons to withhold treatment with ranibizumab.

**c) Raised intraocular pressure**

Elevated intraocular pressure (IOP), even of >30mm Hg, should not preclude treatment provided the IOP is treated simultaneously.

**d) Intraocular surgery**

It is advised that in the presence of exudative AMD and cataracts, the former should be treated and CNV activity controlled prior to cataract surgery, wherever possible. If CNV is diagnosed after intraocular surgery or there is reactivation of an existing CNV, treatment with ranibizumab can be commenced immediately however attention should be paid to the cataract wound.

**Criteria for not commencing treatment**

It is recommended that treatment with ranibizumab should not be commenced in the presence of

a) Permanent structural damage in the fovea.

b) Evidence or suspicion of hypersensitivity to ranibizumab, or similar product. Such evidence should lead to avoidance of therapy, and alternate treatments sought.

**9.3 Intravitreal drug delivery**

Intravitreal (IVT) injections should only be undertaken by or under the supervision of ophthalmologists experienced in the procedure. There are potentially serious adverse events associated with intravitreal injections: endophthalmitis, cataract, vitreous haemorrhage and retinal detachment. IVT Procedure Guidelines are available on the RCOphth website

http://www.rcophth.ac.uk/docs/publications/published-guidelines/IntravitrealInjectionsJuly2006.pdf

## Location

The procedure may be carried out in theatre or a dedicated clean room in the outpatients' department. For outpatient delivery, the room must be an enclosed, dedicated clean room that is free from interruptions. The room must have good illumination, washable floors (UK Health & Safety Regulations) and the ceiling should be non-particulate in nature (no dust or debris should be able to fall on to operative field). Facilities for surgeon's hand-washing, and the wearing of sterile gloves are essential. Resuscitation facilities must be readily available. A table, couch or reclining chair which allows the patient to lie supine is necessary. The room size should be such as to allow enough space on either side of the table to facilitate the movement of the surgeon and the surgical trolley.

## Minimum Equipment requirement

Sterile eyelid speculum, sterile cotton buds, sterile ophthalmic drape, sterile calipers (millimetre gauge), povidone 5% solution (aqueous based)/iodine wash, syringe (drug may be pre-loaded), drawing up needle, 30 gauge injection needle (a wider needle bore to be used with triamcinolone to prevent crystals jamming during injection), topical anaesthetic. Surgical gloves are mandatory. A surgical mask can be worn if desired.

## Anaesthetic

Topical anaesthesia will suffice in most cases especially when instilled copiously over 5-10minutes prior to injection. Supplementary sub-conjunctival or sub-tenon 1%- 2% lignocaine injection can be given if necessary.

## Patient preparation

On the day of intra-vitreal injection, visual acuity and intra-ocular pressure check are not necessary if a two-stop approach to treatment is carried out. Application of a single use mydriatic to achieve pupillary dilatation is recommended. Check the patient can count fingers immediately after the injection to ensure the retinal artery is perfused.

## Eye Preparation

Topical anaesthesia, followed by Povidone 5% aqueous solution (or equivalent) applied to eyelids, eyelid margins and into the conjunctival sac with a contact time of 60 seconds, is a minimal requirement. Pre-injection broad spectrum topical antibiotics may be used in addition to the minimal requirements.

**Technique:**

Patient preparation
Eye preparation
Drape patient
Insert eyelid speculum, ensure it is well positioned with eyelid margins and eyelashes are away from the site of injection
Instruct the patient to direct gaze away from the injection site
Mark the injection site using the calipers (avoid the horizontal meridians of the globe):

- aphakic/pseudo-phakic patients 3.0-3.5mm from limbus
- phakic patients 3.5-4.0mm from limbus

Use of forceps to steady the eye may occasionally be necessary
The needle of the syringe containing the intravitreal drug is inserted perpendicular through the sclera with tip aimed towards the centre of the globe (avoid any contact with the posterior lens)
Inject appropriate volume (0.05-0.1ml) of the therapeutic agent slowly and carefully
Remove needle slowly
A sterile cotton-tipped applicator may be used to prevent reflux
Check the patient can count fingers or can see hand movements to ensure central retinal artery is perfused.

If patient cannot perceive light and eye is hard on digital palpation:

- Check central retinal artery appearance. It would be very unusual for a volume of 0.05ml of fluid to cause central retinal artery closure. If pressure remains high with vision of no light perception consider anterior chamber paracentesis. Such decompression needs to be achieved within 3-5 minutes. Care needs to be taken if the patient is phakic.
- If pressure remains high but vision is returning consider intravenous acetazolamide.

Apply broad spectrum antibiotic

**Post-injection management (Anti-VEGFs and Triamcinolone acetonide):**

Immediate post-injection examination may be performed on a slit-lamp assessing the wound site for vitreous wick, measuring intra-ocular pressure, assessing central retinal artery and fundoscopy. However this is not mandatory. Consideration should be given to checking the intraocular pressure following intravitreal injection of triamcinolone as it is known to be significantly associated with an intraocular pressure rise. However, this immediate post-operative IOP check is unnecessary with smaller volume injections of $\leq$ 0.09ml especially for agents not known to be associated with IOP rise.

Post-injection broad spectrum topical antibiotics may be given up to 1 week following the injection.

Patients should be given clear instructions what to expect and a telephone number to contact for advice in the event of problem.

Urgent attendance at hospital is required if endophthalmitis is suspected.

Clinic review 4-6 weeks post-injection depending upon therapeutic agent.

### 9.4 Outcomes to be measured

Parameters to be measured include:

1. Visual Acuity (ETDRS) at every out-patient visit
2. OCT at every out-patient visit
3. FFA: as deemed necessary by treating ophthalmologist

Contrast sensitivity is impaired in age related macular degeneration. There is evidence contrast sensitivity is more closely associated with quality of life scores than visual acuity. The measurement of contrast sensitivity prior to starting treatment and at the completion of treatment is recommended but not mandatory.

The collection of quality of life data does not need to be undertaken routinely on patients receiving treatment for age related macular degeneration. Quality of life data collection will be necessary to estimate cost effectiveness of treatment. Quality of life data may need to be collected as part of commissioning arrangements for patients receiving treatment.

The assessment of visual fields, reading speed and electro-diagnostics (ERG) is recommended only as part of a clinical trial, or at the treating ophthalmologist's discretion.

### 9.5 Follow up intervals

Ranibizumab treatment is initiated with a loading phase of three injections at intervals of 4 weeks, followed by a maintenance phase in which patients are monitored with ETDRS (LogMAR) BCVA, history and examination, and OCT and/or angiographic examination. The interval between two doses should not be shorter than 4 weeks.

It is expected that all patients will receive 3 loading doses of ranibizumab, unless there are particular contraindications.

Pegaptanib (Macugen) is given by 6 weekly injections. Current recommendations from NICE are that it is not cost-effective as a first line therapy in the treatment of wet macular degeneration.

### 9.6 Re-treatment decision making

It is recommended that ophthalmologists experienced in the management of patients with age related macular degeneration should decide on changing and with holding treatment.

**Criteria for Continuation of treatment**

After the three loading doses, ranibizumab should be continued at 4 weekly intervals and pegaptanib at 6 weekly intervals if:

a) There is persistent evidence of lesion activity
b) The lesion continues to respond to repeated treatment
c) There are no contra-indications (see below) to continuing treatment.

Disease activity is denoted by retinal, subretinal, or sub-RPE fluid or haemorrhage, as determined clinically and/or on OCT, lesion growth on FFA (morphological), and/or deterioration of vision (functional).

### 9.7 Drug Holding and Cessation of therapy

**Consider temporarily discontinuing treatment if:**

(1) There is no disease activity

The disease should be considered to have become inactive when there is:

a) Absence of FFA leakage or other evidence of disease activity in the form of increasing lesion size, or new haemorrhage or exudates (i.e. no increase in lesion size, new haemorrhage or exudates) even if there is persistent fluid on OCT.
b) No re-appearance or further worsening of OCT indicators of CNV disease activity on subsequent follow up following recent discontinuation of treatment.
b) No additional lesion growth or other new signs of disease activity on subsequent follow up following recent discontinuation of treatment.
c) No deterioration in vision that can be attributed to CNV activity.

(2) There has been one or more adverse events related to drug or injection procedure including:

a) endophthalmitis

b) retinal detachment
c) severe uncontrolled uveitis
d) ongoing periocular infections
e) other serious ocular complications attributable to ranibizumab (drug) or injection procedure
f) thrombo-embolic phenomena, including MI or CVA in the preceding 3 months, or recurrent thrombo-embolic phenomena which are thought to be related to treatment with ranibizumab
g) other serious adverse events (SAE) e.g. hospitalisation

**Consider discontinuing treatment permanently if there is:**

1. A **hypersensitivity** reaction to ranibizumab is established or suspected. A change to pegaptanib or PDT is recommended.

2. Reduction of BCVA in the treated eye to **less than 15 letters (absolute) on 2 consecutive visits** in the treated eye, attributable to AMD in the absence of other pathology

3. Reduction in BCVA of **30 letters or more compared to either baseline and/or best recorded level since baseline** as this may indicate either poor treatment effect or adverse event or both

4. There is evidence of deterioration of the **lesion morphology** despite optimum treatment. Such evidence includes progressive increase in lesion size confirmed with FFA, worsening of OCT indicators of CNV disease activity or other evidence of disease activity in the form of significant new haemorrhage or exudates despite optimum therapy over a 3 consecutive visits.

### 9.8 Discharging patient from Hospital eye clinic follow up

Consider discharging the patient from long term hospital follow up if:

1. The decision to discontinue ranibizumab permanently has been made

2. There is no evidence of other ocular pathology requiring investigation or treatment

3. There is low risk of further worsening or reactivation of wet AMD that could benefit from restarting treatment e.g. very poor central vision and a large, non-progressive, macular scar.

**Practical Points**

**Patients should be advised of the need for frequent monitoring when commencing a course of intravitreal drug treatment for AMD. This will be every 4-6 weeks depending on the anti-VEGF used. Treatment and follow-up may need to be continued for up to and beyond 2 years.**

**Further research is required into appropriate duration and optimal regimen in terms of frequency of injections. It still remains to be seen whether less frequent dosing of ranibizumab than that in the pivotal trials will achieve the same visual benefit.**

**Ranibizumab treatment will only improve vision in a third of patients. The majority will maintain vision and some 10% will not respond to therapy.**

**Pegaptanib treatment will reduce the risk of moderate and severe visual loss but most patients will still lose some vision over 2 years.**

**Patients should understand the risk associated with intravitreal injections and be instructed to report symptoms suggestive of endophthalmitis without delay.**

## 10 Summary –Treatment Algorithm

**(Recommendations for Treatment of Neovascular AMD)**

Intravitreal anti-VEGF may be used to treat all lesion types: classic, predominantly classic, minimally classic, occult and RAP lesions.

**Extrafoveal CNV**: Patients with extrafoveal CNV should be treated with focal laser photocoagulation as described in the MPS protocol or anti-VEGF therapy if the laser treatment induced scotoma might interfere with normal visual function. However, in patients with large extrafoveal classic CNV, or occult CNV with progression, it is justifiable to offer alternative treatment similar to that of juxtafoveal lesions. Where no progression is demonstrable, or vision is not threatened observation is advised.

Laser photocoagulation is not recommended for patients with subfoveal or juxtafoveal CNV because of the immediate visual loss that results from foveal photoreceptor and RPE damage, or later encroachment of the scar on the fovea.

**Subfoveal/juxtafoveal CNV**: it is expected that eyes with subfoveal/juxtafoveal CNV of all lesion types will benefit from treatment.

***Predominantly classic subfoveal/juxtafoveal CNV***: Anti- VEGF treatment is recommended first line. However patients with predominantly classic AMD with subfoveal and juxtafoveal location could be offered PDT or combination treatment in the first instance if regular attendance at clinic is difficult. Visual outcomes with combination therapy may not be as good as with monotherapy with anti- VEGF.

**Occult subfoveal/juxtafoveal CNV**: the use of anti-VEGF is recommended if there is evidence of recent disease progression.

**Minimally classic subfoveal/juxtafoveal CNV**: Intraocular injections of anti-VEGF should be considered as first line treatment.

Treatment of RAP and IPC lesions are based on clinical case series and expert opinion as these lesions have not been systematically studied in large randomised clinical trials.

**Retinal angiomatous proliferations (RAPs):** do not respond well to PDT alone. There are reports of successful treatment of eyes with RAPs treated with repeated injections of anti-VEGFs.

**Idiopathic Polypoidal Choroidopathy (IPC):** normally only patients with macular involvement are treated, unless the central vision is threatened by

persistent or progressive exudation. Direct laser photocoagulation can be used for extrafoveal IPC. Active and symptomatic IPC with subfoveal lesions can be treated with PDT. Anti-VEGF monotherapy as well as combination therapy has also been tried.

When recommending intraocular bevacizumab (Avastin) it is extremely important to inform patients that it is unlicensed for this indication and that it has not undergone the usual rigorous clinical trials and independent evaluation by regulatory authorities. Adequate follow-up information must also be maintained on these patients, and recorded appropriately.

## 11 Management of non- neovascular AMD

### 11.1 Monitoring Progression

The term “dry AMD” is commonly used to cover a range of fundal signs, extending from drusen and pigmentary changes; patchy areas of atrophy to geographic atrophy (GA). This can be very confusing for patients. Terms need to be used carefully. Early AMD should be used to describe drusen and pigmentary changes and not the term ‘dry’ AMD. To avoid confusion the term dry AMD should be reserved for geographic atrophy.

Fundus photography has limited value in assessing and monitoring the progression of atrophic areas. Although it has not been proven scientifically, autofluorescence (AF) imaging is now believed to be the method of choice in imaging GA and hence monitoring of progression of non-neovascular AMD. [359]

### 11.2 Strategies for prevention of late AMD

#### 11.2.1 Laser

The observation of disappearance of drusen after focal laser treatment has lead to numerous clinical trials of using laser as prophylactic treatment of patients with large drusen. [360-363] In most studies, focal laser treatment increases the risk of CNV, in particular in the fellow eyes of unilateral neovascular AMD. However, patients who did not develop CNV had better vision after laser treatment. Instead of using focal laser, a large spot size lower power (diffuse) laser is currently under investigation.

#### 11.2.2 Vitamins/Zinc/Antioxidants/Lutein/ Docoshexaenoic acid – see section 6.2.3

### 11.3 Progressive geographic atrophy

#### 11.3.1 Prediction of progression from early AMD to GA

By examining the serial fundus photographs in the AREDS with GA at the last follow up, the progression was usually characterized by large drusen formation and development of hyperpigmentation, followed by regression of drusen, appearance of hypopigmentation, and ultimately development of GA, sometimes preceded by the appearance of refractile deposits. [364]

AF imaging of patients with GA can be sub-classified based on the appearance of the junctional zone and generalised background. Areas of increased autofluorescence surrounding GA are likely to progress to atrophic area in the short term.[365]

### 11.3.2 Cellular protection

Geographic atrophy is in effect a cellular death of RPE cells. By preventing the cells from going into apoptosis, it might be possible to slow the progression of GA. Several studies are underway to explore this option.

## 11.4 Management

### 11.4.1 Low vision rehabilitation

In many patients with advanced non-neovascular AMD, reading is difficult despite relatively good distance visual acuity. Magnifiers and low vision aids are required for these patients. For those who have lost the foveal vision, a preferential retinal locus (PRL) will develop over time. There is some evidence that training using biofeedback can help to develop a more stable PRL.

### 11.4.2 Surgical options

There are at least two implantation systems designed for end-stage AMD. The IOL-Vip system gives a magnification of about 1.3 x and the manufacturer claims that the system redirects the light to the less damaged retina. The IMT system gives a magnification of about 3x but with very restricted visual field. Both systems require post-op specific visual rehabilitation programme.

**Practical Points**

**Treatment for non-neovascular AMD is limited and consists mainly of counselling and rehabilitation.**

## 12 Management of Chronic/Long standing vision loss

### 12.1 The diagnosis session in clinic – general remarks

a. **Breaking bad news**. Patients report that after receiving news that their eye condition is not treatable, they tend not to hear further information during the consultation. It is therefore important that patients are given written information at the end of the consultation concerning their eye condition, available rehabilitation services and useful contact numbers.

b. **Avoid 'diagnose and immediate discharge'**. Patients with macular disease who have lesions which are not treatable with current therapies are often seen only once in the eye clinic and then discharged. They can be unaware of what to expect in the future or where they can obtain relevant information or how to find their way through the maze of services and organisations. Although there may seem little advantage in seeing the patient a second time, because most are not able to take in information after receiving bad news, a follow up visit is of benefit to receive further information and ask questions. They must be given contact details of someone they can come back and talk to. This may be an Eye Clinic Liaison Officer (ECLO).

c. **The clinic experience at time of diagnosis** has an impact on the way patients deal with their diagnosis and visual impairment. Patients frequently report that the diagnosis was given in an uncaring manner. A good initial experience at the hospital will almost certainly help the patient's future outlook, expectations and achievements. A satisfactory patient experience can only be achieved by good training.

d. **Importance of signposting**. Receiving a diagnosis without the follow up information required regarding support services such as visual rehabilitation officers, social services, local help groups such as the RNIB, and Macular Disease Society with delivery of appropriate information and support leaves patients feeling lost and isolated and not knowing where to find help.

e. **Provide literature in the clinic**. Patients appreciate being given information regarding their condition that can be read at leisure. It should be the responsibility of staff in the clinic to make information leaflets available and ensure that patients are offered them before leaving.

f. **Staff Training**. Empathetic handling of a new diagnosis for a patient is a responsibility for the whole unit; continuous staff training is needed. All staff in a unit should be aware of the impact of diagnosis on patients.

## 12.2 What the patient needs to know:

a. **Clear diagnosis**. Make sure the individual knows the name of the condition causing their sight loss and whether they have early AMD or late AMD of the exudative (wet) or atrophic (dry) type AMD or a combination of these, preferably in writing as well as verbally. This means that when they are ready to seek further advice and information they are armed with this vital knowledge. A vague description such as 'you have an eye condition to do with ageing' is not acceptable. They must be told that they have macular degeneration – as above.

b. **Vision prognosis** – what is the outlook for their vision? Will it develop in the second eye? If it is 'dry' could it become 'wet'? It is very important that education regarding the second eye is given. Patients must be informed that if they develop distortion or blurring in their second eye then they need to know how to get back in the system for urgent review.

c. **Treatment options if they exist**.

- All eye department staff need to be aware that even if treatment is not appropriate for a patient with sight loss, individuals can be helped by a range of non-medical supportive measures.
- Eye Departments wherever they are located need to be aware of what is currently available to treat AMD, and if not able to offer one of the current treatments they must make patients aware of the full range of treatments available both on the NHS and privately.
- Phrases such as "nothing more can be done" in a medical sense should be avoided as this terminology can be devastating and unhelpful. The lack of a current therapy does not mean that help in other forms is not available.
- Interventions which can help the individual come to terms with their sight loss, retain their independence, and improve their function and quality life include information about the condition and prognosis, emotional support, counselling, a low vision assessment and practical input such as rehabilitation covering daily living skills, mobility and the benefits of lighting, colour and contrast in maximising the use of residual sight. Some

awareness of the research in the area of retinal repair is helpful as many patients will wish to discuss the current research strategies; two examples are stem cells and electronic eye research.

- All staff and the patient need to be aware of the need to treat exudative AMD urgently. Patients should be told to contact the clinic if they have not received an appointment for treatment or further assessment within 2 weeks.

d. **Hallucinations -Charles Bonnet Syndrome (CBS)**. Many patients with macular degeneration suffer or will suffer from having visual hallucinations. People see different images, from simple patterns of straight lines to detailed pictures of people or buildings. These can be enjoyable or sometimes upsetting. If they have not been warned about the possibility of CBS occurring they may become severely distressed by the thought that they could be developing a serious mental illness. They will be afraid to mention it to anyone else including friends and family or even to their GP. The anxiety is more damaging than the hallucinations themselves. Patients should be alerted to the possibility of CBS which typically improves by 18 months but can last many years. The Macular Disease Society is familiar with the condition and can talk to patients and provide a leaflet.

e. **Risk and improvement factors**. Patients have no control over their age, genes or gender but they should be alerted to the other risk factors itemised below:

- **Smoking** is a recognised risk factor for both dry and wet AMD. All patients with macular degeneration/ dystrophy should be advised to stop smoking. The NHS Stop Smoking Service telephone number is 0800 169 0 169 or www.givingupsmoking.co.uk Recent studies show that smoking reduces the protective effects of antioxidants in the eye and damages the structure of the eye. [Detailed references for these studies can be found elsewhere in RCO guidelines and patient information sheets concerning smoking] Smokers are three times more likely to develop AMD than non-smokers
- **Diet and nutrition**.
  - Diet: eat a diet rich in fruit and vegetables (sources of antioxidant vitamins), include oily fish (source of omega-3 fatty acids) and sources of lutein/zeaxanthin (fruit and vegetables and eggs). These measures are not proven conclusively to be beneficial but they will not do any harm and may be useful given what we know about the biology of the retina.

- Nutritional supplements: There are now many a vast number of different nutritional supplements for eye health available. Only the AREDS formula is proven to be beneficial in people with intermediate and advanced AMD but note: beta-carotene is contraindicated in smokers and potential side-effects of high dose zinc (eg hospitalisation for genitourinary conditions in men). Other supplements eg, lutein/zeaxanthin and omega-3 fatty acids not proven beneficial but currently under test.

- **Bright sunlight** may be a contributory factor in the development of AMD but this is not proven. It is certainly true that patients with AMD are severely affected by the glare of sunlight and therefore good quality anti-glare lenses are essential. The Macular Disease Society leaflet 'Anti-glare Spectacles' provides further information.

e. **Continuing ocular exams** – why and how often

- The importance of ongoing regular eye examinations must be clearly explained to the patient, especially if they are likely to be discharged from the hospital system. Too often individuals never attend for any form of eye examination once diagnosis of a condition leading to sight loss has occurred, failing to understand that an eye examination is a good indicator of general health and provides an early warning for the development of other eye conditions. Cataract may worsen over the years reducing vision further and removal may be indicated.
- Individuals should be advised to attend their optician at least every two years or more frequently if relevant. It may be necessary to explain the GOS system and their possible entitlement to a "free" eye examination.
- There are restrictions on how often a person can have a free eye examination, in which case they will be charged the private eye examination fee.
- They are entitled to NHS free eye examination if they are:
  - Over 60 years old.
  - Under 16 or under 19 & still in full time education.
  - A person with diabetes or glaucoma.
  - Aged 40 or over and have a close relative with glaucoma.
  - Considered to be at risk of Glaucoma by an ophthalmologist.
  - Registered blind or partially sighted
  - Need a prescription classed as complex lenses
  - They or partner receives the following benefits: income support, income based job seekers allowance or named on a tax credit exemption certificate
  - Updates on these categories can be found at

http://www.nhs.uk/aboutnhs/howtheNHSworks/opticians/Pages/OpticiansFAQ.aspx

f. **Date of next appointment** – discharged or still on the books

g. **Change of vision**. Individuals must be advised what they should do if they experiences a sudden change in vision, this may be to contact or attend the eye department within 1 week preferably. The eye department staff must be aware of the need for this group of patients to be seen urgently.

## 12.3 Referral to rehabilitation and low vision services

a. If an individual has sight loss then it is vital that they be offered the opportunity of accessing low vision support and advice at an early stage. Advice and use of task lighting and magnifiers reduce the early impact of sight loss and the risk of falls. Do not wait until all treatment options have been explored or until an individual's vision deteriorates to a level that registration as blind/ severely sight impaired or as partially sighted/ sight impaired becomes appropriate; before considering referring an individual to low vision and rehabilitation services.

b. Early advice and support means that an individual can learn how to use their remaining vision more effectively, retaining independence and confidence. It is also far easier to learn the principles of using optical low vision aids with the lower powers and the skills can be transferred to the higher powers later if needed. The longer it is left the more difficult it is to help a person overcome any loss of confidence in their abilities and the more likely that depression will occur.

c. Find out where and what low vision services are available locally and refer your patients with low vision as soon as possible. Some may well be hospital based and others may be community based.

d. It should no longer be the case that access to a low vision service is certification/ registration led.

e. Extracts from the published (Jan 2007) DoH Recommended Low Vision Standards can be found below, detailing what one should be able to expect from a low vision service. The full documentation can be found at http://www.eyecareservices.nhs.uk/review.aspx

The principles:

- Access to rehab and low vision support will vary according to local arrangements. Clinicians should be present or represented on their local low vision committee. All local systems should adhere to these principles:

- Low vision services must reflect a multi-disciplinary, multi-agency approach that co-ordinates with other health and social care providers in the area, including services provided at the client's residence at the time. This methodology ensures efficient and professional delivery of services.

- The services delivered must be based upon needs identified by clients and be sufficiently flexible to meet the disparate needs of its client group. There should be evidence of user participation in agreements on the setting up and implementation of pathways and protocols.

- Registration as sight impaired or severely sight impaired should not be a pre-requisite to accessing low vision services.

- Locally designed guidelines, pathways and protocols should be underpinned, whenever possible, by evidence based knowledge and accepted guidance. This must conform with and contribute to local clinical governance arrangements.

- Assessment. There should be a tailored needs-based assessment for each client following referral to the low vision service. A low vision assessment should always offer:

    - An eye health examination or evidence of recent examination or referral for examination according to local protocols.
    - A functional visual assessment

- After Assessment the following should be offered, as appropriate, to the user:
    - Prescription/provision of appropriate optical/non-optical aids. The sale of some low vision aids is restricted to certain professionals or requires appropriate supervision. The supply/loan of aids should be governed by local protocol.
    - Advice on lighting, contrast and size, filters, tactile aids, electronic aids and other non-optical aids.
    - Training and/or therapy to enable optical and non-optical aids and other techniques to be used effectively.

- Links to broader rehabilitation services, such as home assessment and mobility as well as possible referral to structured therapy programmes and counselling.
- A review of benefits, welfare rights, concessions, support groups, (both local and national)
- Advice on access to the full range of low vision equipment available for purchase through local society resource centres or the RNIB or direct from retailers.

- If an individual is experiencing difficulties because of problems with their sight they are entitled to an assessment of need by social services – they do not need to be registered as severely sight impaired/ blind or sight impaired/ partially sighted. The level of support offered once an assessment of need has taken place will depend on locally decided criteria, but social services will be able to provide the client information as to the advice and support that is available in an area for people with sight loss and on any services that they may be eligible for.

- In some areas social services will contact patients via the sensory impairment teams' rehabilitation officers for the visually impaired. Rehabilitation officers can provide training and support to a person with sight loss in their homes and local environment to cover daily living and mobility skills. Helping an individual to retain their independence. They can also provide practical advice on how to use remaining vision effectively including the use of lighting, colour and contrast, which can be extremely beneficial even when their is minimal reduction to visual quality. It does not take long for people to lose confidence in their abilities as their sight deteriorates and for many this can lead to depression.

## 12.4 Registration

### a. What is registration

- Each local council keeps a register of blind and partially sighted people living in its area. The register is held by the social services or social work department, or by a local voluntary agency.
- The Certificate of Visual Impairment (CVI) was introduced in 2003 and is used to certify people as blind or partially sighted. Concessions are calculated from the date of examination.
- Hospital eye services can download the Word version of the CVI form for tailoring with their own contact details from the NHSweb, or by emailing OPDEnquiries@dh.gsi.gov.uk.

- This form formally certifies someone as partially sighted or as blind so that the local council can register him or her. Its second purpose is to record a standard range of diagnostic and other data that may be used for epidemiological analysis.

b. **Why register** somebody as blind/ severely sight impaired or as partially sighted/ sight impaired?

- Recent figures for the numbers of people registered as blind/ severely sight impaired or as partially sighted/ sight impaired have dropped significantly since the introduction of the (CVI). There may be many reasons for this, but it certainly does not reflect a drop in the numbers of people experiencing sight loss.

- If anything evidence based on the aging population predicts a sharp increase in the numbers of visually impaired individuals in the coming years. The services for people with sight loss are decreasing in some areas because of this drop in the numbers of people being registered as blind/ severely sight impaired or as partially sighted/ sight impaired

- Epidemiology and prevalence data in the UK is based on the information contained within processed CVIs. If they are not completed for whatever reason then the future planning of health and social care services will be flawed.

- Social Services still base their budget allocations for support to people with Sight Loss on the number of CVIs that they receive. A reduction in registrations means that funding is allocated elsewhere. Many visually impaired people may not choose to be or are never offered the opportunity to become registered as blind/ severely sight impaired or as partially sighted/ sight impaired.

- Certification is also the trigger for a review of benefits that an individual may receive. The benefits that an individual may be entitled to include:

    - Working tax credit
    - There are increased personal income tax allowances for people who are registered blind, if they don't work allowances can be transferred to a working partner
    - Parking concessions (e.g. A blue badge and discs permitting parking in restricted areas)
    - Anyone who is registered blind can claim a 50% reduction in the cost of their television licence. (People over 75 do not have to pay for their TV licence).

- A free radio from the wireless for the blind fund
- Free directory enquiries service from BT
- Talking books from your local library service
- Concessionary travel
- Leisure centre concessions
- Free NHS sight test
- Free postage on items marked 'articles for the blind'

## 12.5 Signposts to others who will provide support

a. "Signposting" to others who can provide information, support and advice is vital. Not knowing how to access information or what help is available is cited by people with sight loss as the biggest barrier to coming to terms with their sight loss.

b. Signposting may be the provision of contact details so the individual can find out further details for themselves. Useful details to pass on would include:
   - contact number for local sensory impairment teams – most councils have a single entry point duty telephone number
   - Local VI society contact details
   - Knowledge of local low vision services referral mechanisms and access criteria
   - The Macular Disease Society – the specialist niche charity providing support for people with Macular Degeneration offers
     - Information and support to individuals with sight loss through telephone helpline 0845 241 2041
     - Over 30 information leaflets in print or audio format
     - Free telephone counselling
     - Member quarterly magazine and annual journal summarising research developments
     - In some areas - Post diagnosis support desks run by MDS and other voluntary groups
     - Network of 150 volunteer led self support groups
     - Website: www.maculardisease.org

## 13 AMD Referral Pathways




The aim at this stage must be to obtain a diagnosis

| | |
|---|---|
| GP | The GP must regard all self referrals as exudative wet AMD and therefore as urgent<br>The GP can refer patients to an optometrist or to a District General Hospital Eye Service or to a Specialist medical retinal centre |
| Optician/ Optometrist | Ideally optometrists should refer exudative AMD cases direct to a specialist medical retinal centre with an established rapid access pathway<br>If this referral line has not been established patients will be sent to a District General Hospital Eye Service<br>The common practice of sending the patient to the GP for onward referral should not happen. It causes delay and is an unnecessary link in the chain. GPs should be informed only.<br>Referral forms to be used by optometrists for suspected exudative AMD patients can be found on this link: http://www.rcophth.ac.uk/docs/scientific/publications/RCOAccessFormv3a.pdf |
| Eye Casualty | Because of potential delays the Macular Disease Society and RNIB help lines advise patients who have experienced a sudden change of vision to present themselves to eye casualty or obtain an urgent appointment in a specialist eye clinic. This will also apply to patients whose referral is delayed. |

## Diagnosis and Onward Referral

| Exudative AMD | Geographic AMD |
|---|---|
| See next page for RCOphth referral chart and notes | |
| Give patient clear diagnosis and information | |
| Best supportive care – see Section 12<br><br>Referral to Low Vision Clinic for assessment and issue of low vision aids and for access to purchased low vision equipment<br><br>Low vision clinic should notify social services where rehabilitation and a home visit is needed<br><br>Registration using the CVI – this is likely to be in the patients interest if their sight is poor enough to meet the criteria<br><br>Fitness to drive: Clinicians assessment<br><br>Sign posting to other agencies for information and support including counselling if needed:<br><br>For example: The Macular Disease Society tel 0845 241 2041<br><br>RNIB tel 0845 766 9999<br>Local society for the visually impaired<br>Nearest low vision / resource centre | |

Referral systems can only work if discussions and training have been held locally between consultant ophthalmologists at specialist retinal centres, in District General Hospital eye units and with optometrists. The LOC should be involved with development of effective local pathways.

Consultant ophthalmologists should also be involved with their local low vision committee in order to establish effective pathways for referring patients into low vision and social services rehabilitation

## WET AMD REFERRAL AND TREATMENT PATHWAY



**Ideals to aim for:**
**t = <1 week from optometrist to Fast Track Clinic**
**t = <1 week from Fast Track Clinic to treatment**

### 13.1 AMD Referral Pathways – notes to amplify the flow chart

### 13.1 AMD Referral Pathways – notes to amplify the flow chart

As set out above, immediate rapid access to retinal specialists with expertise in the management of exudative AMD for all patients should be available, irrespective of geographic location. Patients should be seen by a specialist with medical retinal expertise within one week of diagnosis, and, there should be no more than one week between evaluation and treatment.

All patients suspected to have exudative AMD by the optometrist, general practitioner, or other health workers should be referred directly to the nearest AMD Centre, Eye Casualty, or Eye Clinic. Optometrists may be used for 'screening' or first examination of patients suspected of having exudative AMD. Referrals from the optometrist should be sent directly to an ophthalmology department, and should not pass through the general practitioner as such a route introduces unnecessary delays. Self referral or presentation to the Eye Casualty/Clinic or AMD Centre of exudative AMD should be encouraged, especially in patients who have second eye involvement. Optometrists with specialist interest ('Super Optometrist') are not recommended as such pathways will introduce unnecessary delays, and misdiagnoses.

#### Patient movement through the clinic

It is assumed that all new patients with CNV secondary to AMD referred to an AMD Centre, will undergo an extended assessment of vision, retinal imaging (FFA and OCT), ophthalmological examination, and then proceed to treatment within one week of diagnosis. At subsequent follow-up visits also, treatment would be expected to follow vision assessment, retinal imaging and ophthalmological assessment if indicated.

An integrated clinic for AMD patients is ideal. The pathway in such an integrated clinic would include visual assessments, OCT imaging. This may be in the form of virtual clinics where colour and OCT imaging can be reviewed and patients requiring treatment can be identified. Medical assessments and FFA can be triggered from these clinics as appropriate. Treatments such as - intravitreal

injections (and/or PDT 3 monthly) can be booked as appropriate subsequent to imaging review.

Movement of patients through the AMD clinic depends on whether a 'ONE STOP' or 'TWO STOP' model is adopted. In a 'One Stop' Model all examinations, investigations and treatments are undertaken on the same day, whilst in a 'Two Stop' Model examinations and investigations take place on one day, followed by treatments during a separate visit. A 'one stop' model is preferable as it minimises patient visits to the clinic, especially as some of them may have to travel significant distances. This has to be balanced against the moderate increase in the total time spent by each patient at each visit. Ultimately the model adopted by units will depend on staffing and resources.

### Practical Points

**Patients with exudative macular degeneration need assessed and treated promptly to gain maximum benefit from treatment. The Macular Specialist has a leading role in ensuring clear referral pathways exist both within Ophthalmology departments, and in liaising externally with community optometrists and other referrers to encourage appropriate rapid access pathways for referral and management of these patients**

**Patients should have information provided in clinics with respect to support and rehabilitation services.**

## 14 Miscellaneous

### 14.1 Audit

This will be an important part of any Macular Service and should include audit of the referral pathway, number and frequency of injections, complications and visual outcomes. Normal audit principles and practice would be expected as for any clinical service.
(http://www.rcophth.ac.uk/docs/profstands/ophthalmic-services/AuditandClinicalEffectivenessApril2008.pdf)

It will be important to demonstrate that patients with wet macular degeneration are seen and treated promptly to ensure that maximum benefit from these expensive drugs is obtained.

The fact that National Institute for Health and Clinical Excellence (NICE) has concluded that treatment with ranibizumab is only cost effective if the manufacturer pays for the costs of treatment beyond 14 injections will require careful auditing.

## 14.2 Research

The Final appraisal determination from NICE, August 2008, recommends that further research into the effectiveness of anti- VEGFs in exudative AMD could include studies:

- To clarify the relative clinical effectiveness and cost effectiveness of ranibizumab compared to bevacizumab.
- To investigate the long term effects of anti- VEGFs in patients with AMD, including effects on visual acuity, anatomical damage to the macula, quality of life and adverse events.
- To establish the appropriate duration and optimal treatment regimen in terms of frequency of injections.

## 14.3 Next Review Date

**January 2012 or earlier if necessary.**

## GLOSSARY

**ADVS-** The ADVS (The Activities of Daily Vision Scale) is a 20 item quality of life measurement questionnaire.

**AMD-** Age- related macular degeneration

**ANCHOR- AN**ti- VEGF antibody for the treatment of predominantly classic **CHOR**oidal neovascularisation in age- related macular degeneration study. A phase 3 active-treatment controlled trial of 2 years duration in 422 patients.

**AREDS-** Age- related eye disease study

**ARVO-** Annual Meeting of the Association for Research in Vision and Ophthalmology

**AVMD-** Adult vitelliform macular dystrophy

**BCVA-** Best Corrected Visual Acuity

**CATT-** Comparison of AMD Treatments Trials

**CEE-** Conjugated Equine Oestrogens

**CNV-** Choroidal neovascularization

**CNVM-** Choroidal neovascular membrane

**CRA-** Chorioretinal anastomosis

**CSR-** Central serous retinopathy

**CS**- Contrast sensitivity

**DHA**- docosahexaenoic acid

**DVA-** Distance visual acuity

**DLTV-** The Daily Living Tasks Dependent on Vision (DLTV) is a quality of life (QOL) questionnaire that was constructed to obtain estimates of self-reported ability to perform vision-related tasks in persons with visual impairment due to age-related macular degeneration (AMD).

**ECLO-** Eye Clinic Liaison Officer

**EMEA-** European Medicines Agency

**EPA-** eicosapentaenoic acid

**Fab-** Fragment antigen binding portion

**FAZ-** Foveal avascular zone

**FD-** Fourier Domain

**FOCUS-** A phase 1/2 randomised single- masked study of ranibizumab in combination with PDT + verteporfin in 162 patients with predominantly classic CNV.

**FFA-** Fundus fluorescein angiography

**FA-** Fluorescein angiography

**FAF-** Fundus autofluorescence

**FPED-** Fibrovascular pigment epithelial detachment

**GA-** Geographic atrophy

**GLD-** Greatest linear diameter

**HOPE-** The Heart Outcomes Prevention Evaluation Study

**IPC-** Idiopathic polypoidal choroidopathy

**ICGA-** Indocyanine green angiography

**IVAN-** A randomised controlled trial of alternative treatments to **I**nhibit **V**EGF in **A**ge-related choroidal **N**eovascularisation.

**IVTA-** intravitreal triamcinalone

**LLIO-** Late leakage of indeterminate origin

**LOV-** Local Optical Committee

**LVQOL-** low vision quality-of-life questionnaire (**LVQOL**)

**MacDQoL-** The MacDQoL is an individualized measure of the impact of macular degeneration (MD) on quality of life (QoL)

**MACTEL-** Macular telangiectasia

**MAI-** Philadelphia Geriatric Center Multilevel Assessment Instrument

**MARINA-** Minimally classic/occult trial of Anti- VEGF antibody ranibizumab in the treatment of Neovascular Age- related macular degeneration. A phase 3 randomised sham controlled trial in 716 patients.

**MLVQ-** Manchester low vision questionnaire.

**MPSG-** Macular photocoagulation study group

**NEI-VFQ-** National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25), designed to measure vision-specific health-related quality of life on a scale of 0 to 100 (100 indicates best possible functioning).

**NICE- National Institute of Health and Clinical Excellence**

**OCT-** Optical coherence tomography

**P-** Progestin

**PD-** Pattern dystrophy

**PED-** Pigment epithelial detachment

**PIER-** A phase 3b, multicentre, randomised, double-masked, sham injection controlled study in 184 patients of the efficacy and safety of ranibizumab in subjects with subfoveal choroidal neovascularisation with or without classic CNV secondary to age-related macular degeneration.

**PrONTO-** Prospective OCT imaging of (40) patients with Neovascular AMD Treated with IntraOcular Lucentis. Patients received monthly injections for three months and retreatment decisions were based on OCT results.

**PROTECT-** An open label mulicentre phase 2 Study assessing the safety of same day ranibizumab administered in conjunction with PDT in patients with occult or predominantly classic subfoveal CNV secondary to AMD.

**QoL-** Quality of Life

**RADICAL-** this study is looking at the combination of PDT + ranibizumab+ dexamethaone

**RAP-** Retinal angiomatous proliferation.

**RPE-** Retinal pigment epithelium.

**SAILOR-** A phase 3b, multicentre study to evaluate the safety and tolerability of ranibizumab in Naïve and previously treated subjects (n=5000) with CNV secondary to AMD.

**SLO-** Scanning laser ophthalmoscope

**SNP**- Single nucleotides polymorphisms

**SUMMIT-** these trials consist of the Denali (US) and Mont Blanc (Europe) looking at the safety and efficacy of PDT and ranibizumab.

**SUSTAIN-** One year multicentre open label study in 542 patients with classic or occult CNV. Patients received intravitreal injections of ranibizumab 0.3mg once a month for 3 months followed by criteria-based re-treatment for a total of 12 months.

**TAP** - Treatment of Age-Related Macular Degeneration with Photodynamic Therapy.

**TTT-** transpupillary thermotherapy

**VA-** visual acuity

**VCM1-** Vision core module 1 (**VCM1**)

**VEGF-** Vascular Endothelial Growth Factor

**VERITAS-** Verteporfin Intravitreal Triamcinalone Acetonide Study

**Verteporfin (Visudyne) -** a drug used as a photsensitiser in conjunction with a non-thermal photodynamic (PDT) laser.

**VF-14-** The VF-14 is a health survey questionnaire designed specifically for ophthalmology. "VF" stands for Visual Function, and "14" refers to the 14 questions in the main section of the questionnaire.

**VIO-** Visudyne in Occult Choroidal Neovascularisation

**VIP- AMD**- Verteporfin in Photodynamic Therapy-AMD [VIP-AMD]

**VIP-PM**- Verteporfin in Pathological Myopia

**VISION studies-** VEGF inhibition study in ocular neovascularization

**VPDT-** Verteporfin in Photodynamic Therapy

**VQoL-** Vision Specific Quality of Life (**VQOL**) questionnaire

**WARMGS-** Wisconsin Age-Related Maculopathy Grading Scheme


## Acknowledgements

Shona Burman- Roy and Jennifer Wood at the Eyes and Vision Specialist Library performed the original searches for the epidemiology section. The search strategy they developed is available at

http://evslarchive.moorfields.nhs.uk/amd_docs_0607/ref3.pdf


## Conflict of Interest

The Chair of this group has provided advice and acted as consultant to the following organisations; Pfizer, Allergan, Novartis, Jerini, Neovista and Oraya and accepted speaking engagements and honoraria on their behalf. The commercial relationships of the other members of the group have been declared to the Chair.

## Useful Sources of Information

Ophthalmic Mutal Insurance Company- www.omic.com provides informed consent documents for a wide variety of ophthalmological procedures which can be modified if necessary.

## References

1. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol. 2003 Mar;87(3):312-7.

2. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. . Ophthalmology 98:1128-1134.

3. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995 Mar-Apr;39(5):367-74.

4. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis,elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000 May;14(7):835-46.

5. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol. 2001 Nov;132(5):668-81.

6. Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, Lindblad AS, Milton RC,Bressler SB, Klein R; Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005 Nov;123(11):1570-4.

7. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol. 2004 Jan-Feb;49(1):25-37.

8. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006 Apr;124(4):450-60.

9. Kwan AS, Barry C, McAllister IL, Constable I. Fluorescein angiography and adverse drug reactions revisited: the Lions Eye experience. Clin Experiment Ophthalmol. 2006 Jan-Feb;34(1):33-8.

10. Yannuzzi LA, Rohrer KT, Tindel LJ, Sobel RS, Costanza MA, Shields W, Zang E. Fluorescein angiography complication survey. Ophthalmology. 1986 May;93(5):611-7.

11. [No authors listed]. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep;109(9):1242-57.

12. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Trans Am Ophthalmol Soc. 1994;92:91-111; discussion 111-6.

13. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997 Jan;104(1):7-21.

14. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study. Arch Ophthalmol. 2003 Apr;121(4):519-26.

15. Wang JJ, Foran S, Smith W, Mitchell P. Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort. Arch Ophthalmol. 2003 May;121(5):658-63.

16. Bressler SB, Maguire MG, Bressler NM, Fine SL. Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration. The Macular Photocoagulation Study Group. Arch Ophthalmol. 1990 Oct;108(10):1442-7.

17. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2007 Feb;114(2):253-62.

18. Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol. 1983 Aug;118(2):213-27.

19. Sandberg MA, Tolentino MJ, Miller S, Berson EL, Gaudio AR. Hyperopia and neovascularization in age-related macular degeneration. Ophthalmology. 1993 Jul;100(7):1009-13.

20. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MO. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol. 1988 Oct;128(4):700-10.

21. Wang JJ, Mitchell P, Smith W. Refractive error and age-related maculopathy: the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci. 1998 Oct;39(11):2167-71.

22. Ikram MK, van Leeuwen R, Vingerling JR, Hofman A, de Jong PT. Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3778-82.

23. Ulvik SO, Seland JH, Wentzel-Larsen. Refraction, axial length and age-related maculopathy. Acta Ophthalmol Scand. 2005 Oct;83(5):419-23.

24. Gibson JM, Shaw DE, Rosenthal AR. Senile cataract and senile macular degeneration: an investigation into possible risk factors. Trans Ophthalmol Soc U K. 1986;105 ( Pt 4):463-8.

25. Klein R, Klein BE, Jensen SC, Cruickshanks KJ. The relationship of ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol. 1998 Apr;116(4):506-13.

26. Hirvelä H, Luukinen H, Läärä E, Sc L, Laatikainen L. Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology. 1996 Jun;103(6):871-7.

27. Wang JJ, Jakobsen KB, Smith W, Mitchell P. Refractive status and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2004 Jun;32(3):255-8.

28. Mitchell P, Smith W, Wang JJ. Iris color, skin sun sensitivity, and age-related maculopathy. The Blue Mountains Eye Study. Ophthalmology. 1998 Aug;105(8):1359-63.

29. Hyman LG, Lilienfeld AM, Ferris FL 3rd, Fine SL. Senile macular degeneration: a case-control study. Am J Epidemiol. 1983 Aug;118(2):213-27.

30. Weiter JJ, Delori FC, Wing GL, Fitch KA. Relationship of senile macular degeneration to ocular pigmentation. Am J Ophthalmol. 1985 Feb 15;99(2):185-7.

31. Holz FG, Piguet B, Minassian DC, Bird AC, Weale RA. Decreasing stromal iris pigmentation as a risk factor for age-related macular degeneration. Am J Ophthalmol. 1994 Jan 15;117(1):19-23.

32. Sandberg MA, Gaudio AR, Miller S, Weiner A. Iris pigmentation and extent of disease in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994 May;35(6):2734-40.

33. West SK, Rosenthal FS, Bressler NM, Bressler SB, Munoz B, Fine SL, Taylor HR. Exposure to sunlight and other risk factors for age-related macular degeneration. Arch Ophthalmol. 1989 Jun;107(6):875-9.

34. Nicolas CM, Robman LD, Tikellis G, Dimitrov PN, Dowrick A, Guymer RH, McCarty CA. Iris colour, ethnic origin and progression of age-related macular degeneration. Clin Experiment Ophthalmol. 2003 Dec;31(6):465-9.

35. Tomany SC, Wang JJ, Van Leeuwen R, Klein R, Mitchell P, Vingerling JR, Klein BE, Smith W, De Jong PT. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology. 2004 Jul;111(7):1280-7.

36. Tomany SC, Cruickshanks KJ, Klein R, Klein BE, Knudtson MD. Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol. 2004 May;122(5):750-7.

37. Tomany SC, Klein R, Klein BE; Beaver Dam Eye Study. The relationship between iris color, hair color, and skin sun sensitivity and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003 Aug;110(8):1526-33.

38. Mares-Perlman JA, Millen AE, Ficek TL, Hankinson SE. The body of evidence to support a protective role for lutein and zeaxanthin in delaying chronic disease. Overview. J Nutr. 2002 Mar;132(3):518S-524S.

39. O'Connell E, Neelam K, Nolan J, Au Eong KG, Beatty S. Macular carotenoids and age-related maculopathy. Ann Acad Med Singapore. 2006 Nov;35(11):821-30.

40. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34.

41. Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE, Wright JD. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol. 2001 Mar 1;153(5):424-32.

42. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE. Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci. 2001 Jan;42(1):235-40.

43. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso. Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol. 1988 Oct;128(4):700-10.

44. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD,Gragoudas ES, Haller J, Miller DT, et al. Dietary carotenoids, vitamins A, C,

and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA. 1994 Nov 9;272(18):1413-20.

45. Beatty S, Murray IJ, Henson DB, Carden D, Koh H, Boulton ME. Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci. 2001 Feb;42(2):439-46.

46. Gale CR, Hall NF, Phillips DI, Martyn CN. Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2461-5.

47. Snellen EL, Verbeek AL, Van Den Hoogen GW, Cruysberg JR, Hoyng CB. Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol Scand. 2002 Aug;80(4):368-71.

48. Mares-Perlman JA, Brady WE, Klein R, Klein BE, Bowen P, Stacewicz-Sapuntzakis M, Palta M. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch Ophthalmol. 1995 Dec;113(12):1518-23.

49. Mares-Perlman JA, Klein R, Klein BE, Greger JL, Brady WE, Palta M, Ritter LL. Association of zinc and antioxidant nutrients with age-related maculopathy. Arch Ophthalmol. 1996 Aug;114(8):991-7.

50. VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BE, Brady WE, Palta M. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol. 1998 Jul 15;148(2):204-14.

51. Sanders TA, Haines AP, Wormald R, Wright LA, Obeid O. Essential fatty acids, plasma cholesterol, and fat-soluble vitamins in subjects with age-related maculopathy and matched control subjects. Am J Clin Nutr. 1993 Mar;57(3):428-33.

52. Flood V, Smith W, Wang JJ, Manzi F, Webb K, Mitchell P. Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2002 Dec;109(12):2272-8.

53. Cho E, Seddon JM, Rosner B, Willett WC, Hankinson SE. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol. 2004 Jun;122(6):883-92.

54. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC, Klaver CC, Hofman A, de Jong PT. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA. 2005 Dec 28;294(24):3101-7.

55. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004 Apr;75(4):216-30.

56. http://www. nei. nih. gov/neitrials/viewStudyWeb. aspx?id=120, accessed 15/2/2007

57. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang JJ, de Jong PT. Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 2001 Apr;108(4):697-704

58. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains. Eye Study. Arch Ophthalmol. 2002 Oct;120(10):1357-63.

59. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA. 1996 Oct 9;276(14):1147-51.

60. Klein R, Knudtson MD, Cruickshanks KJ, Klein BE. Further observations on the association between smoking and the long-term incidence and progression of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol. 2008 Jan;126(1):115-21.

61. Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye Study. Am J Epidemiol. 2002 Oct 1;156(7):589-98.

62. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA. 1996 Oct 9;276(14):1141-6.

63. Tan JS, Mitchell P, Kifley A, Flood V, Smith. Smoking and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Arch Ophthalmol. 2007 Aug;125(8):1089-95

64. Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv Ophthalmol. 1998 May-Jun;42(6):535-47.

65. Chakravarthy U, Augood C, Bentham GC, de Jong PT, Rahu M, Seland J, Soubrane G,Tomazzoli L, Topouzis F, Vingerling JR, Vioque J, Young IS,

Fletcher AE. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology. 2007 Jun;114(6):1157-63. Epub 2007 Mar 6.

66. Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JR, Bradley M, Moore AT, Bird AC; Genetic Factors in AMD Study. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006 Jan;90(1):75-80.

67. Kelly SP, Thornton J, Lyratzopoulos G, Edwards R, Mitchell P. Smoking and blindness. BMJ. 2004 Mar 6;328(7439):537-8.

68. Obisesan TO, Hirsch R, Kosoko O, Carlson L, Parrott M. Moderate wine consumption is associated with decreased odds of developing age-related macular degeneration in NHANES-1. J Am Geriatr Soc. 1998 Jan;46(1):1-7.

69. Ritter LL, Klein R, Klein BE, Mares-Perlman JA, Jensen SC. Alcohol use and age-related maculopathy in the Beaver Dam Eye Study. Am J Ophthalmol. 1995 Aug;120(2):190-6.

70. Moss SE, Klein R, Klein BE, Jensen SC, Meuer SM. Alcohol consumption and the 5-year incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology. 1998 May;105(5):789-94.

71. Smith W, Mitchell P. Alcohol intake and age-related maculopathy. Am J Ophthalmol. 1996 Nov;122(5):743-5.

72. Ajani UA, Christen WG, Manson JE, Glynn RJ, Schaumberg D, Buring JE, Hennekens CH. A prospective study of alcohol consumption and the risk of age-related macular degeneration. Ann Epidemiol. 1999 Apr;9(3):172-7.

73. Cho E, Hankinson SE, Willett WC, Stampfer MJ, Spiegelman D, Speizer FE, Rimm EB, Seddon JM. Prospective study of alcohol consumption and the risk of age-related macular degeneration. Arch Ophthalmol. 2000 May;118(5):681-8.

74. Cruickshanks KJ, Hamman RF, Klein R, Nondahl DM, Shetterly SM. The prevalence of age-related maculopathy by geographic region and ethnicity. The Colorado-Wisconsin Study of Age-Related Maculopathy. Arch Ophthalmol. 1997 Feb;115(2):242-50.

75. Chong EW, Kreis AJ, Wong TY, Simpson JA, Guymer RH. Alcohol Consumption and the Risk of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2008 Jan 31 [Epub ahead of print].

76. Finkel T,. Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-47.

77. Beatty S, Koh HH, Phil M, Henson D, Boulton M. The Role of Oxidative Stress in the Pathogenesis of Age-Related Macular Degeneration. Surv. Ophthalmol. 2000;45:115-34.

78. Goldberg J, Flowerdew G, Smith E, Brody JA, Tso MOM. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am. J. Epidemiol. 1988;128:700-10.

79. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994;272:1413-20.

80. Mares-Perlman JA, Klein R, Klein BE, Greger JL, Brady WE, Palta M et al. Association of zinc and antioxidant nutrients with age-related maculopathy. Arch Ophthalmol 1996;114:991-7.

81. VandenLangenberg GM, Mares-Perlman JA, Klein R, Klein BEK, Brady WE, Palta M. Associations between Antioxidant and Zinc Intake and the 5-Year Incidence of Early Age-related Maculopathy in the Beaver Dam Eye Study. Am. J. Epidemiol. 1998;148:204-14.

82. Christen WG, Ajani UA, Glynn RJ, Manson JE, Schaumberg DA, Chew EC et al. Prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy. Am. J. Epidemiol. 1999;149:476-84.

83. Smith W, Mitchell P, Webb K, Leeder SR. Dietary antioxidants and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 1999;106:761-7.

84. Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE et al. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am. J. Epidemiol. 2001;2001 Mar 1;153:424-32.

85. Cho E, Hung S, Willett WC, Spiegelman D, Rimm EB, Seddon JM et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am. J. Clin. Nutr. 2001;73:209-18.

86. Flood V, Smith W, Wang JJ, Manzi F, Webb K, Mitchell P. Dietary antioxidant intake and incidence of early age-related maculopathy : The blue mountains eye study. Ophthalmology 2002;109:2272-8.

87. Kuzniarz M, Mitchell P, Flood VM, Wang JJ. Use of vitamin and zinc supplements and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2002;9:283-95.

88. Snellen ELM, Verbeek ALM, van den Hoogen GWP, Cruysberg JRM, Hoyng CB. Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmologica Scandinavica 2002;80:368-71.

89. Cho E, Seddon JM, Rosner B, Willett WC, Hankinson SE. Prospective Study of Intake of Fruits, Vegetables, Vitamins, and Carotenoids and Risk of Age-Related Maculopathy. Arch Ophthalmol 2004;122:883-92.

90. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JCM, Klaver CCW, Hofman A et al. Dietary Intake of Antioxidants and Risk of Age-Related Macular Degeneration. JAMA 2005;294:3101-7.

91. Moeller SM, Parekh N, Tinker L, Ritenbaugh C, Blodi B, Wallace RB et al. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Intitiative. Arch Ophthalmol 2006;124:1151-62.

92. Eye Disease Case-Control Study Group. Antioxidant status and neovascular age-related macular degeneration. Arch Ophthalmol 1993;111:104-9.

93. West S, Vitale S, Hallfrisch J, Munoz B, Muller D, Bressler S et al. Are antioxidants or supplements protective for age-related macular degeneration? Arch Ophthalmol 1994;112:222-7.

94. Mares-Perlman JA, Brady WE, Klein R, Klein BE, Bowen P, Stacewicz-Sapuntzakis M et al. Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch Ophthalmol 1995;113:1518-23.

95. Delcourt C, Cristol JP, Tessier F, Leger CL, Descomps B, Papoz L. Age-related macular degeneration and antioxidant status in the POLA study. POLA Study Group. Pathologies Oculaires Liees a l'Age. Arch Ophthalmol 1999;117:1384-90.

96. Simonelli F, Zarrilli F, Mazzeo S, Verde V, Romano N, Savoia M et al. Serum oxidative and antioxidant parameters in a group of Italian patients with age-related maculopathy. Clinica Chimica Acta 2002;320:111-5.

97. Dasch B, Fuhs A, Schmidt J, Behrens T, Meister A, Wellmann J et al. Serum levels of macular carotenoids in relation to age-related maculopathy: the Muenster Aging and Retina Study (MARS). Graefes Arch Clin. Exp. Ophthalmol. 2005;243:1028-35.

98. Chong EW, Kreis EJ, Wong TY, Simpson AJ, Guymer RH. Dietary antioxidants and primary prevention of age-related macular degeneration: a systematic review and meta-analysis. BMJ 2007;335:755.

99. Evans JR,. Henshaw K. Antioxidant vitamin and mineral supplementation for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2000;CD000253.

100. Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2006;519;CD000254.

101. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;2001 Oct;119:1417-36.

102. The Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J Med. 1994;330:1029-35.

103. Omenn G. S. , Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 1996;334:1150-5.

104. The HOPE and HOPE-TOO Trial Investigators. Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial. JAMA 2005;293:1338-47.

105. Chong EW, Kreis EJ, Wong TY, Simpson AJ, Guymer RH. Dietary omega-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: a systematic review and meta-analysis. Arch Ophthalmol 2008;126:826-33.

106. Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992;110:1701-8.

107. Delcourt C, Michel F, Colvez A, Lacroux A, Delage M, Vernet MH et al. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol. 2001;8:237-49.

108. Seddon JM, Cote J, Davis N, Rosner B. Progression of Age-Related Macular Degeneration: Association With Body Mass Index, Waist Circumference, and Waist-Hip Ratio. Arch Ophthalmol 2003;121:785-92.

109. AREDS. Risk factors associated with age-related macular degeneration ; A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology 2000;107:2224-32.

110. Age-Related Eye Disease Study Group. Risk Factors for the Incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS): AREDS report no. 19. Ophthalmology 2005;112:533-9.

111. Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index and the incidence of visually significant age-related maculopathy in men. Arch Ophthalmol 2001;119:1259-65.

112. Smith W, Mitchell P, Leeder SR, Wang JJ. Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 1998;116:583-7.

113. Klein BE, Klein R, Lee KE, Jensen SC. Measures of obesity and age-related eye diseases. Ophthalmic Epidemiol 2001;8:251-62.

114. Hirvela H, Luukinen H, Laara E, Sc L, Laatikainen L. Risk factors of age-related maculopathy in a population 70 years of age or older. Ophthalmology 1996;103:871-7.

115. Cheung N, Wong TY. Obesity and eye diseases. Survey Ophthalmology 2007;52: 180-195.

116. Wong T,. Mitchell P. The eye in hypertension. Lancet. 2007;369:425-35.

117. AREDS. Risk factors associated with age-related macular degeneration ; A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology 2000;107:2224-32.

118. Hyman L, Schachat AP, He Q, Leske MC, for the Age-Related Macular Degeneration Risk Factors Study Group. Hypertension, Cardiovascular Disease, and Age-Related Macular Degeneration. Arch Ophthalmol 2000;118:351-8.

119. Klein R, Klein BEK, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: The Beaver Dam eye study. Ophthalmology 2003;110:636-43.

120. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3771-7.

121. Hogg RE, Woodside JV, Gilchrist SECM, Graydon R, Fletcher AE, Chang W, Knox A, Cartmill B, Chakravarthy U. Cardiovascular disease and hypertension

are strong risk factors for choroidal neovascularisation. Ophthalmology 2008; 115: 1046-52.

122. Fraser-Bell S, Wu J, Klein R, Azen SP, Hooper C, Foong AWP, Varma R. Cardiovascular risk factors and age-related macular degeneration: The Los Angeles Latino Eye Study. Am J Ophthalmol 2008;145: 308-316.

123. Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1993;100:406-14.

124. Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Oshima Y, Ishibashi T et al. Risk factors for age related maculopathy in a Japanese population: the Hisayama study. Br J Ophthalmol 2003;87:469-72.

125. Klein R, Klein BEK, Marino EK, Kuller LH, Furberg C, Burke GL et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003;110:25-33.

126. Wong TY, Tikellis G, Sun C, Klein R, Couper DJ, Sharrett AR. Age-Related Macular Degeneration and Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. Ophthalmology 2007;114:86-91.

127. Wong TY, Klein R, Sun C, Mitchell P, Couper DJ, Lai H et al. Age-Related Macular Degeneration and Risk for Stroke. Ann Intern Med 2006;145:98-106.

128. AREDS Research Group. Associations of Mortality With Ocular Disorders and an Intervention of High-Dose Antioxidants and Zinc in the Age-Related Eye Disease Study: AREDS Report No. 13. Arch Ophthalmol 2004;122:716-26.

129. Tan JS, Wang JJ, Liew G, Rochtchina E, Mitchell P. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol. 2008 Feb 29 [Epub ahead of print]

130. Alexander SL, Linde-Zwirble WT, Werther W, Depperschmidt EE, Wilson LJ, Palanki R, Saroj N, Butterworth SL, Ianchulev T. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology. 2007 Dec;114(12):2174-8.

131. Guymer RH, Chiu AW, Lim L, Baird PN. HMG CoA Reductase Inhibitors (Statins): Do They Have a Role in Age-related Macular Degeneration? Surv. Ophthalmol. 2005;50:194-206.

132. Hall NF, Gale CR, Syddall H, Phillips DIW, Martyn CN. Risk of macular degeneration in users of statins: cross sectional study. The BMJ 2001;323:375-6.

133. McGwin G, Jr. , Owsley C, Curcio CA, Crain RJ. The association between statin use and age related maculopathy. Br J Ophthalmol 2003;87:1121-5.

134. McGwin J, Xie A, Owsley C. The use of cholesterol-lowering medications and age-related macular degeneration. Ophthalmology 2005;112:488-94.

135. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol. 2004;137:615-24.

136. Klein R, Klein BEK, Tomany SC, Danforth LG, Cruickshanks KJ. Relation of Statin Use to the 5-Year Incidence and Progression of Age-Related Maculopathy. Arch Ophthalmol 2003;121:1151-5.

137. Smeeth L, Cook C, Chakravarthy U, Hubbard R, Fletcher AE. A case control study of age related macular degeneration and use of statins. Br J Ophthalmol 2005;89:1171-5.

138. van Leeuwen R, Vingerling JR, Hofman A, de Jong PT, Stricker BH. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255-6.

139. Chuo JY, Wiens M, Etminan M, Maberley DAL. Use of lipid-lowering agents for the prevention of age-related macular degeneration: a meta-analysis of observational studies. Ophthalmic Epidemiology 2007;14: 367-74.

140. Snow KK,. Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol 1999;6:125-43.

141. Lotery,A. & Trump,D. Progress in defining the molecular biology of age related macular degeneration. Hum Genet 122, 219-236 (2007).

142. Edwards,A. O. et al. Complement factor H polymorphism and age-related macular degeneration. Science 308, 421-424 (2005).

143. Haines,J. L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419-421 (2005).

144. Klein,R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389 (2005).

145. Yates,J. R. et al. Complement C3 Variant and the Risk of Age-Related Macular Degeneration. N Engl J Med 357, 553-561 (2007).

146. Hughes,A. E. et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 38, 1173-1177 (2006).

147. Gold,B. et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 38, 458-462 (2006).

148. Rivera,A. et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum. Mol. Genet. 14, 3227-3236 (2005).

149. DeWan,A. et al. HTRA1 Promoter Polymorphism in Wet Age-Related Macular Degeneration. Science1133807 (2006).

150. Yang,Z. et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314, 992-993 (2006).

151. Fisher,S. A. et al. Meta-analysis of genome scans of age-related macular degeneration. Hum. Mol. Genet. 14, 2257-2264 (2005).

152. Schmidt,S. et al. Cigarette Smoking Strongly Modifies the Association of LOC387715 and Age-Related Macular Degeneration. The American Journal of Human Genetics 78, 852-864 (2006).

153. Goverdhan,S. V. et al. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye(2007).

154. Brantley Jr,M. A. et al. Association of Complement Factor H and LOC387715 Genotypes with Response of Exudative Age-Related Macular Degeneration to Intravitreal Bevacizumab. Ophthalmology 114, 2168-2173 (2007).

155. Leveziel,N. et al. Genotype-phenotype correlations for exudative Age-related Macular Degeneration associated with homozygous HTRA1 and CFH genotypes. Invest Ophthalmol Vis. Sci. (2008).

156. Leveziel,N. et al. PLEKHA1-LOC387715-HTRA1 polymorphisms and exudative age-related macular degeneration in the French population. Mol. Vis. 13, 2153-2159 (2007).

157. Souied,E. H. et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol. Vis. 11, 1135-1140 (2005).

158. Weger,M. et al. Association of the HTRA1 -625G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population. Mol. Vis. 13, 1274-1279 (2007).

159. Wegscheider,B. J. et al. Association of Complement Factor H Y402H Gene Polymorphism with Different Subtypes of Exudative Age-Related Macular Degeneration. Ophthalmology 114, 738-742 (2007).

160. Lau,L. I. et al. Association of the Y402H Polymorphism in Complement Factor H Gene and Neovascular Age-Related Macular Degeneration in Chinese Patients. Invest. Ophthalmol. Vis. Sci. 47, 3242-3246 (2006).

161. Brantley,M. A. et al. Clinical Phenotypes Associated with the Complement Factor H Y402H Variant in Age-related Macular Degeneration. American Journal of Ophthalmology 144, 404-408 (2007).

162. Klein R, Klein BE, Wang Q, Moss SE. Is age-related maculopathy associated with cataracts? Arch Ophthalmol. 1994 Feb;112(2):191-6.

163. Wang JJ, Klein R, Smith W, Klein BE, Tomany S, Mitchell P. Cataract surgery and the 5-year incidence of late-stage age-related maculopathy: pooled findings from the Beaver Dam and Blue Mountains eye studies. Ophthalmology. 2003 Oct;110(10):1960-7.

164. Armbrecht AM, Findlay C, Kaushal S, Aspinall P, Hill AR, Dhillon B. Is cataract surgery justified in patients with age related macular degeneration? A visual function and quality of life assessment. Br J Ophthalmol. 2000 Dec;84(12):1343-8.

165. Wong TY. Cataract surgery in patients with cataract and age related macular degeneration: do the benefits outweigh the risks? Br J Ophthalmol. 2000 Dec;84(12):1337-8.

166. Cugati S, de Loryn T, Pham T, Arnold J, Mitchell P, Wang JJ. Australian prospective study of cataract surgery and age-related macular degeneration: rationale and methodology. Ophthalmic Epidemiol. 2007 Nov-Dec;14(6):408-14.

167. Freeman EE, Munoz B, West SK, Tielsch JM, Schein OD. Is there an association between cataract surgery and age-related macular degeneration? Data from three population-based studies. Am J Ophthalmol. 2003 Jun;135(6):849-56.

168. Klein R, Klein BE, Wong TY, Tomany SC, Cruickshanks KJ. The association of cataract and cataract surgery with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Arch Ophthalmol. 2002 Nov;120(11):1551-8.

169. Wang JJ, Mitchell PG, Cumming RG, Lim R. Cataract and age-related maculopathy: the Blue Mountains Eye Study. Ophthalmic Epidemiol. 1999 Dec;6(4):317-26.

170. Klein R, Klein BE, Wong TY, Tomany SC, Cruickshanks KJ. The association of cataract and cataract surgery with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Arch Ophthalmol. 2002 Nov;120(11):1551-8.

171. Presentation title: The Effect of Cataract Surgery on the Development of Neovascular Age-Related Macular Degeneration (AMD). Abstract 2175] Association for Research in Vision and Ophthalmology (ARVO) annual meeting. 2006

172. McCarty CA, Mukesh BN, Fu CL, Mitchell P, Wang JJ, Taylor HR. Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol. 2001 Oct;119(10):1455-62.

173. Ham WT Jr, Mueller HA, Sliney DH. Retinal sensitivity to damage from short wavelength light. Nature. 1976 Mar 11;260(5547):153-5.

174. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34.

175. West SK, Rosenthal FS, Bressler NM, Bressler SB, Munoz B, Fine SL, Taylor HR. Exposure to sunlight and other risk factors for age-related macular degeneration. Arch Ophthalmol. 1989 Jun;107(6):875-9.

176. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000 Dec;107(12):2224-32.

177. Tomany SC, Cruickshanks KJ, Klein R, Klein BE, Knudtson MD. Sunlight and the 10-year incidence of age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol. 2004 May;122(5):750-7.

178. Mainster MA. Violet and blue light blocking intraocular lenses: photoprotection versus photoreception. Br J Ophthalmol. 2006 Jun;90(6):784-92.

179. Evans JR. Risk Factors for Age-related Macular Degeneration. Prog. Ret. Eye Res. 2001;20:227-53.

180. Smith W, Mitchell P, Wang JJ. Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust. N. Z. J. Ophthalmol. 1997;25:S13-S15.

181. Snow KK, Cote J, Yang W, Davis NJ, Seddon JM. Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women. American Journal of Ophthalmology 2002;134:842-8.

182. Defay R, Pinchinat S, Lumbroso S, Sutan C, Delcourt C, The Pola Study Group. Sex steroids and age-related macular degeneration in older French women: the POLA study. Ann. Epidemiol. 2004;14:202-8.

183. Nirmalan PK, Katz J, Robin AL, Ramakrishnan R, Krishnadas R, Thulasiraj RD et al. Female Reproductive Factors and Eye Disease in a Rural South Indian Population: The Aravind Comprehensive Eye Survey. Invest. Ophthalmol. Vis. Sci. 2004;45:4273-6.

184. Abramov Y, Borik S, Yahalom C, Fatum M, Avgil G, Brzezinski A et al. The effect of hormone therapy on the risk for age-related maculpathy in postmenopausal women. Menopause 2004;11:62-8.

185. Freeman EE, Bressler SB, West SK. Hormone replacement therapy, reproductive factors, and age-related macular degeneration: the Salisbury Eye Evaluation Project. Ophthalmic Epidemiol. 2005;12:37-45.

186. Fraser-Bell S, Wu J, Klein R, Azen SP, Varma R. Smoking, Alcohol Intake, Estrogen Use, and Age-related Macular Degeneration in Latinos: The Los Angeles Latino Eye Study. American Journal of Ophthalmology 2006;141:79-87.

187. Klein BE, Klein R, Lee KE. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women: the beaver dam eye study. American Journal of Ophthalmology 2000;130:322-6.

188. AREDS. Risk factors associated with age-related macular degeneration ; A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology 2000;107:2224-32.

189. Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992;110:1701-8.

190. Vingerling JR, Dielemans I, Witteman JCM, Hofman A, Grobbee DE, de Jong PTVM. Macular degeneration and early menopause: a case-control study. BMJ 1995;310:1570-1.

191. Haan MN, Klein R, Klein BE, Deng Y, Blythe LK, Seddon JM et al. Hormone therapy and age-related macular degeneration: the Women's Health Initiative Sight Exam Study. Arch Ophthalmol 2006;124:988-92.

192. Klein R, Klein BE, Cruickshanks KJ. The prevalence of age-related maculopathy by geographic region and ethnicity. Prog. Ret. Eye Res. 1999;18:371-89.

193. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. American Journal of Ophthalmology 2004;137:486-95.

194. Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. Ophthalmology 1995;102:371-81.

195. Schachat AP, Hyman L, Leske MC, Connell AM, Wu SY. Features of age-related macular degeneration in a black population. The Barbados Eye Study Group. Arch Ophthalmol 1995;113:728-35.

196. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999;106:1049-55.

197. Klein R, Clegg L, Cooper LS, Hubbard LD, Klein BEK, King WN et al. Prevalence of Age-related Maculopathy in the Atherosclerosis Risk in Communities Study. Arch Ophthalmol 1999;117:1203-10.

198. Klein R, Klein BEK, Marino EK, Kuller LH, Furberg C, Burke GL et al. Early age-related maculopathy in the cardiovascular health study. Ophthalmology 2003;110:25-33.

199. Cruickshanks KJ, Hamman RF, Klein R, Nondahl DM, Shetterly SM. The prevalence of age-related maculopathy by geographic region and ethnicity. The Colorado-Wisconsin Study of Age-Related Maculopathy. Arch Ophthalmol 1997;115:242-50.

200. Varma R, Fraser-Bell S, Tan S, Klein R, Azen SP. Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology 2004;111:1288-97.

201. Munoz B, Klein R, Rodriguez J, Snyder R, West SK. Prevalence of Age-Related Macular Degeneration in a Population-Based Sample of Hispanic People in Arizona: Proyecto VER. Arch Ophthalmol 2005;123:1575-80.

202. Age-Related Eye Disease Study Group. Risk factors associated with age-related macular degeneration: A case-control study in the age-related eye

disease study: age-related eye disease study report number 3. Ophthalmology 2000;107:2224-32.

203. Klein R, Klein BE, Jensen SC, Moss SE. The relation of socioeconomic factors to the incidence of early age-related maculopathy: the Beaver Dam eye study. Am J Ophthalmol 2001;132:128-31.

204. Klein R, Klein BEK, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: The national health and nutrition examination survey III. Ophthalmology 1999;106:1056-65.

205. Fraser-Bell S, Donofrio J, Wu J, Klein R, Azen SP, Varma R. Sociodemographic factors and age-related macular degeneration in Latinos: the Los Angeles Latino Eye Study. Am J Ophthalmol 2005;139:30-8.

206. Cheng AS , Vingrys AJ. Visual losses in early age-related maculopathy. Optometry and Vision Science, 1993;70:89-96

207. Eisner A, Klein ML, Zilis JD, Watkins MD. Visual function and the subsequent development of exudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 1992 Oct;33(11):3091-102

208. Owsley C, Jackson GR, White M, Feist R, Edwards D. Delays in rod-mediated dark adaptation in early age-related maculopathy. Ophthalmology, 2001 Jul;108(7):1196-202.

209. Sunness JS, Gonzalez-Baron J, Applegate CA, Bressler NM, Tian Y, Hawkins B, Barron Y, Bergman A. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration Ophthalmology. 1999 Sep;106(9):1768-79

210. Sunness JS, Margalit E, Srikumaran D, Applegate CA, Tian Y, Perry D, Hawkins BS, Bressler NM. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology. 2007 Feb;114(2):271-7

211. Bressler SB, Bressler NM, Fine SL, Hillis A, Murphy RP, Olk RJ, Patz A Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol. 1982 Feb;93(2):157-63

212. Guyer DR, Fine SL, Maguire MG, Hawkins BS, Owens SL, Murphy RP. Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol. 1986 May;104(5):702-5

213. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol. 1986 Apr;104(4):513-4

214. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep;109(9):1220-31.

215. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol. 1993 Sep;111(9):1200-9.

216. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep;109(9):1232-41

217. Macular Photocoagulation Study Group Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1994 Apr;112(4):489-99.

218. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Aug;109(8):1109-14. Erratum in: Arch Ophthalmol 1992 Jun;110(6):761

219. Macular Photocoagulation Study Group Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol. 1994 Apr;112(4):500-9

220. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Arch Ophthalmol. 1999 Oct;117(10):1329-45.

221. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001 Feb;119(2):198-207

222. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1. Ophthalmology. 2001 May;108(5):841-52.

223. Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K,Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008 Jan;115(1):116-26. Epub 2007 Aug 6.

224. Eisner A, Stoumbos VD, Klein ML, Fleming SA. Relations between fundus appearance and function. Eyes whose fellow eye has exudative age-related macular degeneration. Invest Ophthalmol Vis Sci. 1991 Jan;32(1):8-20. Erratum in: Invest Ophthalmol Vis Sci 1991 Apr;32(5):1507.

225. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Macular Photocoagulation Study Group. Arch Ophthalmol. 1994 Apr;112(4):480-8

226. Mangione CM, Gutierrez PR, Lowe G, Orav EJ, Seddon JM. Influence of age-related maculopathy on visual functioning and health-related quality of life. Am J Ophthalmol. 1999 Jul;128(1):45-53.

227. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984 Nov;102(11):1640-2

228. Avila MP, Jalkh AE, Mainster MA, Trempe CL, Weiter JJ, Schepens CL Photofield mapping in the evaluation and management of subretinal neovascularization. Ann Ophthalmol. 1985 Jan;17(1):13-9

229. Hogg R, Curry E, Muldrew A, Winder J, Stevenson M, McClure M, Chakravarthy U. Identification of lesion components that influence visual function in age related macular degeneration. Br J Ophthalmol. 2003 May;87(5):609-14.

230. Doris N, Hart PM, Chakravarthy U, McCleland J, Stevenson M, Hudson C, Jackson J. Relation between macular morphology and visual function in patients with choroidal neovascularisation of age related macular degeneration. Br J Ophthalmol. 2001 Feb;85(2):184-8.

231. Campbell FW and Green DG (1965) Optical and Retinal Factors affecting Visual Acuity J Physiol. , London 181 576-593

232. Wilkins AJ, Della Sala S, Somazzi L and Nimmo-Smith I (1988) Age Related Norms for the Cambridge Low Contrast Gratings including Details Concerning their Design and Use Clin Vision Sci 2:3 201-212

233. Arden GB and Jacobson JJ (1978) A Simple Grating Test for Contrast Sensitivity: Preliminary Results Indicate Value for Screening in Glaucoma Invest Ophthal Vis Sci 17 23-32

234. Ginsburg AP (1984) A New Contrast Sensitivity Vision Test Am J of Optom & Physiol Opts 61 403-407

235. Pelli DG, Robson JG and Wilkins AJ (1988) The Design of a New Letter Chart for Measuring Contrast Sensitivity Clin Vision Sci 2:3 p187-199

236. Arditi A (2005) Improving the Design of the Letter Contrast Sensitivity Test Invest Ophthalmol Vis Sci 46 2225-2229

237. Regan D, Neima D (1983) Low Contrast Letter Charts as a Test of Visual Function Ophthalmology 90 1192-1200

238. Bailey IL (1982) Simplifying Contrast Sensitivity Testing Am J Optom Physiol Optics 59:12

239. Hyvarinen L (2000) Vision Evaluation of Infants and Children in Silverstone B, Long MA, Rosenthal B, Faye E The Lighthouse Handbook on Vision Impairment and Vision Rehabilitation 2 Ch 43 NY : Oxford University Press 799-820

240. Owsley C, Ball K, McGwuin et al (1998) Visual Processing Impairment and Risk of Motor Vehicle Crash among Older Adults JAMA 279 1083-1088

241. Marron JA, Bailey IL (1982) Visual Factors and Orientation – Mobility Performance Am J Optom Physiol Opt 59 413-426

242. Hirvela H, Koskela P, Laatikainen L (1995) Visual Acuity and Contrast Sensitivity in the Elderly Acta Ophthalmol Scand 73 111-115

243. Lord SR, Dayhew J (2001) Visual Risk Factors for Falls in Older People J Am Geriatr Soc 49 508-515

244. Bullimore MA, Bailey IL, Wacker RT (1991) Face Recognition in Age Related Maculopathy Invest Ophthalmol Vis Sci 32 2020-2029

245. Whittaker SG and Lovie Kitchin J (1993) Visual Requirements for Reading Optom Vis Sci 70 54-65

246. Crossland MD, Culham LE, Rubin GS ( ) Predicting Reading Fluency in Patients with Macular Disease Optom Vis Sci 82 11-17

247. Legge GE (1993) The Role of Contrast in Reading : Normal and Low Vision in Shapley R, Lam DM Eds Contrast Sensitivity MIT Press Cambridge MA

248. National Research Council (2002) Visual Impairments : Determining Eligibility for Social Security Benefits 354 National Academy Press Washington D. C.

249. Haegerstrom-Portnay G, Schneck ME and Brabyn JA (1999) Seeing into Old Age : Vision Function beyond Acuity Optom Vis Sci 141-158

250. Haegerstrom-Portnoy G (2003) The Glenn A Fry Award Lecture – Vision in Elders : Summary of Findings of the SKI study Optom Vis Sci 82(2) 87-93

251. Rubin GS, Bandeen-Roche K, Huang CH, Munoz B, Schein OD et al (2001) The Association of Multiple Visual Impairments with Self-Reported Visual Disability (SEE Project) Invest Ophthalmol Vis Sci 42 : 64-72

252. Bellmann C, Unnebrink K, Rubin GS, Miller and Holz FG (2003) Visual Acuity and Contrast Sensitivity in Patients with Neovascular Age Related Macular Degeneration – Results from the Radiation Therapy for Age Related Macular Degeneration (RAD) study Graefes Arch Clin Exp Ophthalmol 241 968-974

253. Kleiner RC, Enger C, Alexander MF and Fine SL (1988) Contrast Sensitivity in Age Related Macular Degeneration Arch Ophthalmol 106 55-57

254. Stangos N, Voutas S, Topouzis F and Karampatakis V (1995) Contrast Sensitivity Evaluation in Eyes Predisposed to Age Related Macular Degeneration and Presenting Normal Visual Acuity Ophthalmologica 209 194-198

255. Brown B, Lovie-Kitchin J (1987a) Contrast Sensitivity in Central and Paracentral Retina in Age Related Maculopathy Clin Exp Optom 70:5 145-148

256. Alexander MF, Maguire MG, Lietman TM et al (1988) Assessment of Visual Function in Patients with Age Related Macular Degeneration and Low Visual Acuity Arch Ophthalmol 106 1543-1547

257. Bansback N, Czoski-Murray C, Carlton J et al (2007) Determinants of Health Related Quality of Life and Health State Utility in Patients with ARMD : The Association of Contrast Sensitivity and Visual Acuity

258. Doris N, Hart PM, Chakravarthy U, McClelland J, Stevenson M, Hudson C et al (2001) Relationship between Macular Morphology and Visual Function in Patients with Choroidal Neovascularisation of ARMD B J Ophthalmol 85 184-188

259. Hogg RE, Chakravarthy U (2006) Visual Function and Dysfunction in Early and Late Age Related Maculopathy Progress in Retinal and Eye Research 25:3 249-276

260. Sunness JS, Rubin GS, Broman A et al (2008) Low Luminance Visual Dysfunction as a Predictor of Subsequent Visual Acuity Loss Resulting from Geographic Atrophy in Age Related Macular Degeneration Ophthalmology (Epub)

261. McClure ME, Hart PM, Jackson AJ, Stevenson MR, Chakravarthy U. Macular degeneration: do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol. 2000 Mar;84(3):244-50.

262. Hart PM, Chakravarthy U, Mackenzie G, Chisholm IH, Bird AC, Stevenson MR, Owens SL, Hall V, Houston RF, McCulloch DW, Plowman N. Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration. Arch Ophthalmol. 2002 Aug;120(8):1029-38

263. Toth CA, Lapolice DJ, Banks AD, Stinnett SS. Improvement in near visual function after macular translocation surgery with 360-degree peripheral retinectomy. Graefes Arch Clin Exp Ophthalmol. 2004 Jul;242(7):541-8. Epub 2004 Jun 5.

264. Mitchell J, Wolffsohn J, Woodcock A, Anderson SJ, Ffytche T, Rubinstein M, Amoaku W, Bradley C. The MacDQoL Individualized Measure of the Impact of Macular Degeneration on Quality of Life: Reliability and Responsiveness. Am J Ophthalmol. 2008 Jun 9

265. Massof R, Rubin G. Visual function assessment questionnaires. Surv Ophthalmol. 2002;45:531-48.

266. de Boer MR, Moll AC, de Vet HC, Terwee CB, Volker-Dieben HJ, van Rens GH. Psychometric properties of vision-related quality of life questionnaires: a systematic review. Ophthalmic Physiol Opt. 2004 Jul;24(4):257-73.

267. Margolis MK, Coyne K, Kennedy-Martin T, Baker T, Schein O, Revicki DA. Vision-specific instruments for the assessment of health-related quality of life and visual functioning: a literature review. Pharmacoeconomics. 2002;20(12):791-812.

268. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health and Quality of Life Outcomes. 2006;4(1):97.

269. Pesudovs K. Patient-centred measurement in ophthalmology--a paradigm shift. BMC ophthalmology. 2006;6:25.

270. Bond T, Fox C. Applying the Rasch Model: Fundamental Measurement in the Human Sciences. Journal of Educational Measurement. 2003;40(2):185-7.

271. Massof RW. Application of stochastic measurement models to visual function rating scale questionnaires. Ophthalmic Epidemiol. 2005 Apr;12(2):103-24.

272. Childs AL, Bressler NM, Bass EB, Hawkins BS, Mangione CM, Marsh MJ, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality-of-life findings: SST report no. 14. Am J Ophthalmol. 2000;130(4):408 - 18.

273. Stevenson MR, Hart PM, Chakravarthy U, Mackenzie G, Bird AC, Owens SL, et al. Visual functioning and quality of life in the SubFoveal Radiotherapy Study (SFRADS): SFRADS report 2. Br J Ophthalmol. 2005;89(8):1045 - 51.

274. Chang TS, Fine JT, Bressler NM. Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 phase iii randomized clinical trials of ranibizumab (LucentisTm). Invest Ophthalmol Vis Sci. 2006;47:E - Abstract 5252.

275. Zlateva G, Patel M, Shah SN, Vegf Inhibition Study in Ocular Neovascularisation Clinical Trial Group. Quality of life in patients with age-related macular degeneration: Results from the VISION study. Invest Ophthalmol Vis Sci. 2006;47:E - Abstract 2152.

276. Wolffsohn JS, Cochrane AL. Design of the low vision quality-of-life questionnaire (LVQOL) and measuring the outcome of low-vision rehabilitation. Am J Ophthalmol. 2000;130(6):793 - 802.

277. Brody BL, Roch-Levecq AC, Thomas RG, Kaplan RM, Brown SI. Self-management of age-related macular degeneration at the 6-month follow-up: a randomized controlled trial. Arch Ophthalmol. 2005;123(1):46 - 53.

278. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol. 2000;118(1):47-51.

279. Sahel JA, Bandello F, Augustin A, Maurel F, Negrini C, Berdeaux GH. Health-related quality of life and utility in patients with age-related macular degeneration. Arch Ophthalmol. 2007 Jul;125(7):945-51.

280. Bansback N, Czoski-Murray C, Carlton J, Lewis G, Hughes L, Espallargues M, et al. Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity. Qual Life Res. 2007 Apr;16(3):533-43.

281. Aspinall PA, Hill AR, Dhillon B, Armbrecht AM, Nelson P, Lumsden C, et al. Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration. Br J Ophthalmol. 2007 Jun;91(6):766-72.

282. [No authors listed]. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Aug;109(8):1109-14.

283. [No authors listed]. Treatment of senile disciform macular degeneration: a single-blind randomized trial by argon laser photocoagulation. The Moorfields Macular Study Group. Br J Ophthalmol. 1982 Dec;66(12):745-53.

284. [No authors listed]. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990 Jun;108(6):816-24.

285. [No authors listed]. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990 Jun;108(6):825-31.

286. [No authors listed]. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Macular Photocoagulation Study Group. Arch Ophthalmol. 1986 Apr;104(4):503-12.

287. [No authors listed]. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep;109(9):1232-41.

288. [No authors listed]. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep;109(9):1220-31. Comment in: Arch Ophthalmol. 1991 Sep;109(9):1217-8.

289. Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in phase 1 and 2 study. Arch Ophthalmol. 1999 Sep;117(9):1161-73.

290. Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM,

Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 1999 Sep;117(9):1177-87.

291. [No authors listed]. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999 Oct;117(10):1329-45.

292. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001 Feb;119(2):198-207.

293. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES,Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baselinelesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002 Nov;120(11):1443-54.

294. Kaiser PK; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006 Sep;244(9):1132-42. Epub 2006 Mar 15.

295. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001 May;131(5):541-60.

296. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M,Su XY, Virgili G; Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization

secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol. 2003 Sep;136(3):407-18.

297. Visudyne In Occult Choroidal Neovascularization; VIO study http://www. medsafe. govt. nz/profs/datasheet/v/Visudyneinf. htm

298. Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, Immonen I, Lim JI, Menchini U, Naor J, Potter MJ, Reaves A, Rosenfeld PJ, Slakter JS, Soucek P, Strong HA, Wenkstern A, Su XY, Yang YC; Visudyne in Minimally Classic Choroidal. Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularizationin age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol. 2005 Apr;123(4):448-57.

299. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005 Feb;112(2):301-4.

300. Chaudhary V, Mao A, Hooper PL, Sheidow TG. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology. 2007 Dec;114(12):2183-9.

301. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol. 2006 Mar;90(3):337-41.

302. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006 Apr;141(4):638-45.

303. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006 Jan;113(1):14-22. Epub 2005 Dec 19.

304. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina. 2006 Jul-Aug;26(6):602-12.

305. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology. 2006 Dec;113(12):2243-50. Epub 2006 Sep 25.

306. Ergun E, Maár N, Ansari-Shahrezaei S, Wimpissinger B, Krepler K, Wedrich A, Stur M. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol. 2006 Jul;142(1):10-16.

307. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina. 2005 Sep;25(6):685-90.

308. Presentation title: Verteporfin Therapy in Combination with Pegaptanib or Triamcinolone for West AMD: 6-Month Results of the VERITAS study. Oral 2870] Association for Research in Vision and Ophthalmology (ARVO) May 2007

309. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor AB. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004 Mar;122(3):336-40.

310. Roth DB, Realini T, Feuer WJ, Radhakrishnan R, Gloth J, Heimmel MR, Fechtner RD, Yarian DL, Green SN. Short-term complications of intravitreal injection of triamcinolone acetonide. Retina. 2008 Jan;28(1):66-70.

311. Rinsing of the Cannula Prior to Intravitreal Injection—Reply Mark C. Gillies. Arch Ophthalmol. 2004;122:1572.

312. Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research Group, Gilson MM, Bressler NM, Jabs DA, Solomon SD, Thorne JE, Wilson DJ. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2007 Sep;114(9):1713-21.

313. Hawkins BS, Bressler NM, Miskala PH, Bressler SB, Holekamp NM, Marsh MJ, Redford M, Schwartz SD, Sternberg P Jr, Thomas MA, Wilson DJ; Submacular Surgery Trials(SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology. 2004 Nov;111(11):1967-80.

314. Ron Y, Ehrlich R, Axer-Siegel R, Rosenblatt I, Weinberger D. Pneumatic displacement of submacular hemorrhage due to age-related macular degeneration. Ophthalmologica. 2007;221(1):57-61.

315. Handwerger BA, Blodi BA, Chandra SR, Olsen TW, Stevens TS. Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement. Arch Ophthalmol. 2001 Jan;119(1):28-32.

316. Hassan AS, Johnson MW, Schneiderman TE, Regillo CD, Tornambe PE, Poliner LS, Blodi BA, Elner SG. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999 Oct;106(10):1900-6; discussion 1906-7.

317. Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol. 1998 Oct;116(10):1326-32.

318. Ibanez HE, Williams DF, Thomas MA, Ruby AJ, Meredith TA, Boniuk I, Grand MG. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol. 1995 Jan;113(1):62-9.

319. de Juan E Jr, Loewenstein A, Bressler NM, Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization II: a preliminary report in humans. Am J Ophthalmol. 1998 May;125(5):635-46.

320. Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1999 Apr;237(4):313-25.

321. Fujikado T, Asonuma S, Ohji M, Kusaka S, Hayashi A, Ikuno Y, Kamei M, Oda K, Tano Y. Reading ability after macular translocation surgery with 360-degree retinotomy. Am J Ophthalmol. 2002 Dec;134(6):849-56.

322. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees retinectomy for neovascular age-related macular degeneration. Ophthalmology. 2004 Sep;111(9):1715-24.

323. Toth CA, Lapolice DJ, Banks AD, Stinnett SS. Improvement in near visual function after macular translocation surgery with 360-degree peripheral retinectomy. Graefes Arch Clin Exp Ophthalmol. 2004 Jul;242(7):541-8. Epub 2004 Jun 5.

324. Wong D, Stanga P, Briggs M, Lenfestey P, Lancaster E, Li KK, Lim KS, Groenewald C. Case selection in macular relocation surgery for age related macular degeneration. Br J Ophthalmol. 2004 Feb;88(2):186-90.

325. Hart PM, Chakravarthy U, Mackenzie G, Chisholm IH, Bird AC, Stevenson MR, Owens SL, Hall V, Houston RF, McCulloch DW, Plowman N. Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration. Arch Ophthalmol. 2002 Aug;120(8):1029-38.

326. Pöstgens H, Bodanowitz S, Kroll P. Low-dose radiation therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1997 Oct;235(10):656-61.

327. Valmaggia C, Ries G, Ballinari P. Radiotherapy for subfoveal choroidal neovascularization in age-related macular degeneration: a randomized clinical trial. Am J Ophthalmol. 2002 Apr;133(4):521-9.

328. Kobayashi H, Kobayashi K. Age-related macular degeneration: long-term results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol. 2000 Nov;130(5):617-35.

329. Anders N, Stahl H, Dorn A, Walkow T, Hosten N, Wust P, Hartmann C, Wollensak J. [Radiotherapy of exudative senile macular degeneration. A prospective controlled study]. Ophthalmologe. 1998 Nov;95(11):760-4.

330. Bergink GJ, Hoyng CB, van der Maazen RW, Vingerling JR, van Daal WA, Deutman AF. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthalmol. 1998 May;236(5):321-5.

331. Char DH, Irvine AI, Posner MD, Quivey J, Phillips TL, Kroll S. Randomized trial of radiation for age-related macular degeneration. Am J Ophthalmol. 1999 May;127(5):574-8.

332. Hoeller U, Fuisting B, Schwartz R, Roeper B, Richard G, Alberti W. Results of radiotherapy of subfoveal neovascularization with 16 and 20 Gy. Eye. 2005 Nov;19(11):1151-6. Comment in:Eye. 2005 Nov;19(11):1137-41.

333. Sivagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004004.

334. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30;351(27):2805-16. Comment in ACP J Club. 2005 Jul-Aug;143(1):18. N Engl J Med. 2004 Dec 30;351(27):2863-5. N Engl J Med. 2005 Apr 21;352(16):1720-1; author reply 1720-1.

335. VEGF Inhibition Study in Ocular Neovascularization (V. I. S. I. O. N. ) Clinical Trial Group; Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled

clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113(9) 1508 (2006).

336. Gonzales CR;VEGF Inhibition Study in Ocular Neovascularization (V. I. S. I. O. N. ) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 25(7), 815-27 (2005).

337. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; 338. Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003 Dec;110(12):2372-83; discussion 2384-5.

338. Slakter JS, Bochow TW, D'Amico DJ, Marks B, Jerdan J, Sullivan EK, Robertson SM, Slakter JS, Sullins G, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology. 2006 Jan;113(1):3-13. Epub 2005 Dec 20.

339. Rosenfeld PJ, Brown DM, Heier JS et al Boyer DS, for the MARINA Study Group. Ranibizumab for neovascular age related macular degeneration. N Engl J Med. 355(14),1419-1431 (2006).

340. Brown DM, Kaiser PK, Michels M et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 355(14),1432-44 (2006).

341. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N; The PIER Study Group. Randomized, Double-Masked, Sham-Controlled Trial of ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1. Am J Ophthalmol. 2008 Feb;145(2):239-248. e5.

342. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007 Apr;143(4):566-83.

343. Lalwani GA, Fung AE, Michels S, Dubovy SR, Feuer WJ Jr. , Puliafito CA, Rosenfeld PJ. An OCT-guided variable-dosing regimen with ranibizumab (Lucentis) in neovascular AMD: two year results of the PrONTO study. Poster presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 7, 2007; Fort Lauderdale, Fla. 2 year PrONTO results

344. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006 May-Jun;26(5):495-511.

345. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4569-78.

346. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006 Apr;26(4):383-90.

347. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006 Mar;113(3):363-372. e5. Epub 2006 Feb 3.

348. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina. 2006 Nov-Dec;26(9):994-8.

349. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 2006 Mar;26(3):270-4.

350. Algvere PV, Steén B, Seregard S, Kvanta A. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Acta Ophthalmol. 2007 Dec 14 [Epub ahead of print]

351. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008 Feb;145(2):249-256. Epub 2007 Dec 11.

352. Madhusudhana KC, Hannan SR, Williams CP, Goverdhan SV, Rennie C, Lotery AJ, Luff AJ, Newsom RS. Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. Br J Ophthalmol. 2007 Dec;91(12):1716-7.

353. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007 Jan;245(1):68-73. Epub 2006 Nov 18.

354. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006 Mar;26(3):262-9.

355. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006 Nov;90(11):1344-9. Epub 2006 Jul 19.

356. Heier JS, Boyer DS, Ciulla TA et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 124(11),1532-42 (2006). Erratum in: Arch Ophthalmol. 125(1),138 (2007).

357. Schmidt-Erfurth UM, Gabel P, Hohman T, PROTECT Study Group. Preliminary results from an open-label, multicenter, phase II study assessing the effects of same-day administration of ranibizumab (Lucentis(TM)) and verteporfin PDT (PROTECT Study). Program and abstracts of the Association for Research in Vision and Ophthalmology; April 30-May 4, 2006; Fort Lauderdale, Florida. Abstract 2960.

358. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007 Feb;27(2):133-40.

359. Holz FG, Bindewald-Wittich A, Fleckenstein M, et al. , Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol. 2007 Mar;143(3):463-72.

360. Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology. 2006 Nov;113(11):1974-86.

361. Friberg TR, Musch DC, Lim JI, Morse L, Freeman W, Sinclair S; PTAMD Study Group. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology. 2006 Apr;113(4):622. e1.

362. Owens SL, Bunce C, Brannon AJ, Xing W, Chisholm IH, Gross M, Guymer RH, Holz FG, Bird AC; Drusen Laser Study Group. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. Am J Ophthalmol. 2006 Feb;141(2):276-81. Comment in: Am J Ophthalmol. 2006 Feb;141(2):354-5.

363. Hsu J, Maguire MG, Fine SL. Laser prophylaxis for age-related macular degeneration. Can J Ophthalmol. 2005 Jun;40(3):320-31.

364. Klein ML, Ferris FL 3rd, Armstrong J, Hwang TS, Chew EY, Bressler SB, Chandra SR; AREDS Research Group. Retinal precursors and the development of geographic atrophy in age-related macular degeneration. Ophthalmology. 2008 Jun;115(6):1026-31. Epub 2007 Nov 5.

365. Schmitz-Valckenberg S, Bindewald-Wittich A, Dolar-Szczasny J,et al. , Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2648-54.